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ABSTRACT OF DISSERTATION

RNA NANOTECHNOLOGY FOR NEXT GENERATION TARGETED
DRUG DELIVERY

The emerging field of RNA nanotechnology is developing into a promising
platform for therapeutically application. Utilizing the state-of-art RNA nanotechnology,
RNA nanoparticles can be designed and constructed with controllable shape, size for both
RNA therapeutics and chemical drug delivery. The high homogeneity in particle size and
ease for RNA therapeutic module conjugation, made it feasible to explore versatile RNA
nanoparticle designs for preclinical studies.
One vital module for therapeutic RNA nanoparticle design is RNA aptamer,
which can enable the RNA nanoparticles find its specific target for targeted drug delivery.
A system of screening divalent RNA aptamers for cancer cell targeting was developed.
The system utilized a highly stable three way junction (3WJ) derived from phi29
bacteriophage packing RNA (pRNA). Instead of using one random loop for aptamer
SELEX as traditionally, the divalent RNA nanoparticle library contains two variable
loops for substrate binding, similar to protein antibodies. The presence of two binding
sites on one aptamer greatly enhanced its affinity, and the thermodynamically stability of
pRNA-3WJ motif enables controllable RNA folding of each loop. The selected RNA

antibody against epithelial adhesion molecule (EpCAM) A9-8 can deliver therapeutic
anti-miR21 to EpCAM positive cancer cells in vitro. The feasibility of using RNA
aptamer for targeted chemical drug delivery is explored. A phosphorothioate bond
modified DNA (thio-DNA) aptamer targeting annexin A2 was utilized as ligand to build
nucleic acid nanoparticles for ovarian cancer targeted drug delivery. A DNA/RNA hybrid
nanoparticle was generated by conjugating the thio-DNA aptamer to pRNA-3WJ motif.
The DNA/RNA hybrid nanoparticles showed favorable property for delivering
doxorubicin to ovarian cancer cells in vitro, also targeted to ovarian cancer xenograft in
bio-distribution study in vivo. Utilizing the spatial orientation of pRNA-3WJ, cholesterol
modification on the arrow tail of pRNA-3WJ can display RNA nanoparticle on the
surface of exosomes/extracellular vesicles (EV) for active targeting. Taking the advantage
of RNA ligand for specific targeting; and exosome for efficient membrane fusion, cytosol
homing and functional siRNA delivery; the RNA ligand decorated exosomes were
constructed for specific delivery of siRNA to cancer cells. PSMA aptamer-displaying
exosomes and encapsulated survivin siRNA (PSMAapt/EV/siSurvivin) showed efficient
gene silencing both in cell culture and animal trials. After systemically injection of
PSMAapt/EV/siSurvivin to prostate cancer xenograft mice, cancer growth was almost
completely blocked. These results suggest the advance of RNA nanotechnology can
further drive its way towards clinical application as a novel next generation drug delivery
system.

KEYWORDS: RNA Nanotechnology, Phi29 packaging motor, aptamer, SELEX,
exosomes, prostate cancer, ovarian cancer
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Chapter 1: Introduction and Literature Review
BRIEF SUMMARY:
Chapter 1 begins this thesis with an overview on the RNA nanotechnology and its
application for targeted drug delivery. First the current status and promise of
nanotechnology and RNA nanoparticles for drug delivery system are examined. Next the
status of RNA aptamers development, the advancement of aptamer selection method, its
application and advantages for clinical application are discussed. Finally, Extracellular
vesicles (EVs) as an emerging field in therapeutics and diagnosis is introduced, including
its biogenesis, native functions in biological organism, regulation of its secretion. The
application extracellular vesicles as new generation therapeutics as well as drug delivery
vehicles are discussed.
Chapter 2 looks at the development of bivalent RNA aptamers targeting to cancer
stem cell marker epithelial cell adhesion molecule (EpCAM). The highly stable three way
junction (3WJ) derived from phi29 DNA packaging motor pRNA was utilized as a core
motif to construct an antibody shaped RNA library with two random regions for binding
region selection. The extracellular domain of EpCAM protein was used as target for RNA
aptamer selection. The selected divalent 2’F-pyrimidine modified RNA aptamers can
bind specifically to its target with KD value around 100nM. The selected EpCAM
aptamer can bind to EpCAM positive cancer cells and specifically delivery locked
nucleic acid (LNA) based anti-miR21 into cancer cells and induce cancer cell apoptosis.
Chapter 3 studies how to utilize the orientation of pRNA-3WJ to control RNA
loading or surface display on extracellular vesicles for efficient cancer cell targeting,
1

siRNA delivery and cancer regression. Placing a membrane anchoring cholesterol
molecule at the arrow tail of pRNA-3WJ resulted displaying of RNA aptamer or folate
ligand on to the surface of extracellular vesicles. Taking advantage of the RNA aptamer
ligand for specific targeting and EVs for efficient membrane fusion, the resulting RNA
aptamer-displaying EVs were used for specific delivery of siRNA with efficient gene
silencing resulting in complete blockage of cancer growth. Animal studies showed that
the nanometer scale ligand-displaying EVs specifically localized in tumor xenografts
without accumulating in healthy organs. Efficient gene silencing was observed both in
cell culture and animal trials from systemic administration of Prostate Membrane
Specific Antigen (PSMA) aptamer-displaying EVs loaded with survivin siRNA.
Chapter 4 studies the application of RNA aptamer harboring nanoparticles for
ovarian cancer targeted delivery of chemotherapeutics doxorubicin. A multifunctional
RNA nanoparticle harboring phosphorothioate bond modified DNA aptamer targeting
annexin A2 protein, and GC rich sequence for intercalating doxorubicin was designed
and constructed. The highly stable pRNA-3WJ structural motif provides a rigid core to
the RNA architecture and disfavors misfolding of aptamers when conjugated to other
oligonucleotides, while keep their affinity and functions intact. Thus, this nanoparticle
design is of significance utility for aptamer mediated targeted delivery. The nanoscale
RNase-resistant RNA nanoparticles remained intact after systemic injection in mice and
accumulated specifically to tumors with little or no accumulation in healthy organs 6 h
post-injection. The RNA nanoparticle/doxorubicin intercalates showed enhanced toxicity
to ovarian cancer cells with annexin A2 overexpressing, but reduced toxicity to annexin
A2 negative cells in cell toxicity assay. These results suggest that the constructed
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nanoparticle can potentially enhance ovarian cancer targeted doxorubicin delivery for
cancer treatment at lower doses with enhanced efficacy.
Chapter 5 studies the discovery of a new method for potent drug development
using power function of stoichiometry of homomeric biocomplexes or biological
nanomotors. Targeting multisubunit homomeric biological motors with a sequential
action mechanism, highly potent drugs can be developed. Inhibiting multisubunit tragets
with sequential actions resembles breaking one bulb in a series of Christmas lights, which
turns off the entire string. Besides the drug binding affinity, the potency of drug
inhibition depends on the stoichiometry of targeted biological complexes. As biomotors
with multi-subunits are widespread in viruses, bacterial and cells, this approach should
have general application in the development of inhibition drugs with high efficiency.
Most viral DNA packaging motors contain a high-stoichiometry machine composed of
multiple components that work cooperatively and sequentially. Thus, it is an ideal target
for potent antiviral drug development.
Chapter 6 briefly summarizes the major findings in the way of RNA
nanotechnology for pharmaceutical application discussed in this thesis dissertation.
Furthermore, the future direction of this work is described providing a prospective on
research that is still needed to move forwards the application of RNA nanotechnology.
Finally, the current state of RNA nanotechnology is discussed looking at the major
hurdles that have been solved and look at how the recent advancements can drive RNA
nanotechnology into the cancer therapy.
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HYPOTHESIS:
The 3WJ motif from Phi29 bacteriophage packaging RNA (pRNA) provides a
stable RNA scaffold for the construction of nanoparticles for the treatment of cancers.
LITERATURE REVIEW:
1.1 Nanotechnology and drug delivery
Nanotechnology is a young scientific field that represents a vast variety of
disciplines ranging from fundamental material science to many applied sciences
including pharmaceutics. The application of nanotechnology in medicine is referred to as
nanomedicine, which has profound impact to improve the efficacy of chemotherapeutics
and gene therapeutics, also improve diagnostic sensitivity for early disease diagnosis(1)
by enhancing tumor targeting and reduce its systemic toxicity, given the premise of
developing intelligent drug delivery systems.
Nanomedicine field is undergoing a revolution in the recent years. A wide variety
of nanoparticle materials are studied and used in nanomedicine. The varieties of material
include liposomes, polymeric micelles, dendrimers, quantum dots, iron oxide particles,
carbon nanotubes, and nucleic acid based nanoparticles (2-4). The most exciting concept
of nanomedicine research is the emerging of multifunctional nanoparticles. They
normally include multiple mix and matched functionalities, include components of ligand
for targeting nanoparticles to a specific location; linkers and core structures that give the
nanoparticle defined shape and size; therapeutic or diagnostic cargoes that either
encapsulated or conjugated to the nanoparticles; and sometimes with a proper coating
material to improve its bioavailability and biocompatibility(3). For example, chemical
drugs can be loaded into traditional nano-delivery systems such as micelle (5), polymer

4

nanoparticles (6), liposome (7), carbon nanomaterials (8), quantum dots (9,10), and gold
nanoparticles (11) for in vivo tumor targeted imaging and therapy. Nanomedicine is also
harnessed for the delivery of gene therapeutics including RNAi drugs.
RNA interference is an innate cell machinery to regulate gene expression by
noncoding RNA, which mainly includes small interfering RNA (siRNA) and micro RNA
(miRNA). The short single stranded miRNAs can form duplexes with its complementary
mRNA sequences in the 3’untranslated region. RNAi inhibits specific target gene
expression either by mRNA degradation or translation inhibition. MiRNA mediated
mRNA degradation normally occurs only when the miRNA perfectly matches its target
mRNA; partially complementary to target mRNA sequence inhibits the mRNA
translation with even a single nucleotide base change (12). The challenges to apply RNAi
based therapies include their cellular uptake, bio-distribution, stability, off-target effect
and toxicity in vitro and in vivo. The negative charge of RNAi molecules makes them
difficult to cross cell plasma membrane (13). To enhance cellular uptake of RNAi,
traditional transfection techniques, such as electroporation, gene gun, microinjection, and
viral transfection can be employed in vitro; but not for in vivo systemically administration.
To facilitate clinical application of RNAi treatment, passive tissue targeting and active
cellular targeted delivery strategies are explored. Passive targeting strategies mainly
utilize positively charged natural or artificial polymer materials forming complex with
negatively charged RNAi for delivery. Stable nucleic acid-lipid particles (SNALP) are
lipid based nanoparticles which encapsulate RNAi payloads by forming complex between
the cationic lipid with negative charged RNA(14). The concern for SNALPs is its
accumulation in liver and toxicity for liver, kidney and immune system(15), thus it is not
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used for human testing. 1.2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) (16),
histidine-lysine peptides (17), atelocollagen rich in positively charged amino acids (17)
have been used for siRNA delivery through passive targeting by EPR effect. Active
cellular targeting is a very promising direction for systemic delivery. Different
approaches have been studied for loading siRNA to achieve target cell specific delivery.
Cholesterol siRNA conjugates mainly targets liver(18); N-acetylgalactosamine modified
dynamic

polyconjugates

mainly

targets

the

asialoglycoprotein

receptor

on

hepatocytes(18); RGD (Arg-Gly-Asp) peptide modified PEI (polyehtyleneimine)
complex mainly targets integrins which is a receptor highly expressed on cancer cells and
extracellular matrix around tumor(18); transferrin conjugated PEG-cylodextrin
containing poly-cationic (CDP) particles targets transferrin receptors expressed on many
tumors(19); the specific ligand expressed as fusion proteins composed of mAb fragments
with positively charged human truncated protamine targets specific receptor expression
cells(20); aptamer siRNA chimeras also provided a new platform for specific cell
targeted siRNA delivery(21). The siRNA delivery systems under clinical trials now are
mainly CDP nanoparticles, SNALP liposomes for systemic administration, and local
administration by intravitreal injection or inhalation (13).
The well-known EPR (enhanced permeability and retention) effect is a major
mechanism for nanomedicines getting accumulated in tumors and thus distinguishes the
nanomedicine from traditional small chemical drugs. In fact, whether EPR effect is
sufficient to achieve the desired enhanced therapeutic effect in human is questioned. EPR
effect only offers around 2-fold increase tumor environment than normal organs in fact
(22), as the tumor microenvironment is quite complex. The tumor vasculature usually has
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incomplete endothelial lining thus having larger pores leading to higher vascular
permeability and hydraulic conductivity (23). However, there are multiple barriers to the
nanodelivery systems to reach tumor cells, except for the clearance by mononuclear
phagocyte systems (MPS) for larger nanoparticles or by kidney glomerular filtration for
smaller nanoparticles, the abnormal tumor vasculature, the high interstitial fluid pressure
in tumor tissue, the solid mechanical stress produced by tumor growth and abnormal
extracellular matrix in tumor tissue all created barriers for extravasation of nanoparticles
to penetrate into tumors(22). Methods to improve the EPR effect of nanodelivery systems
including modulating the tumor blood flow, modulating the tumor vasculature and stroma
and killing the cancer cells to reduce barrier functions are under intensive study(24). A
very promising way to improve the therapeutic effect of nanomedicine stratagem call
Near infrared photo immunotherapy involves using a targeted monoclonal antibody
conjugated to a photon absorber IR Dye 700, where the EGFR targeting antibody directed
nanoparticles to bind tumor cell membrane, 24 h post administration, the tumor was
exposed to NIR light at 690 nm thus induces nearly immediate necrotic tumor cell
death(25).
Birth of RNA nanotechnology
Advancement in nanotechnology paved the way for developing more
sophisticated drug delivery systems for transporting varieties of bio-functional molecule
to the desired site for diagnosis and treatment. The field of DNA nanotechnology had
significant progress recent years, DNA nanostructures have been employed as smart
imaging agents or delivery platforms on living organisms. Nucleic acid based
nanoparticles have advantage over inorganic nanoparticles for in vivo application
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including their high purity, easy production and reproducibility, biocompatibility and
biodegradability (26).
DNA nanotechnology was initialized by Nadrian C. Seeman in early 1980s, after
the discovery of double-helical, G quadruplexes, X or Y-shaped DNA (27). Three
dimensional nanostructures can be designed and constructed with single strand and
double stranded DNA sequences, with confined shape and structure, exploiting the
Watson-Crick base paring principle. Sticky ends of DNA were used as toeholds for selfassembly process, thus the building blocks of DNA nanoparticles can be precisely
controlled(28). Novel DNA origamis was constructed with a 7249nt long circular plasmid
DNA from virus M13mp18 with more than 200 short DNA oligoes as staple strands(29),
which can fold the long single strand DNA at specific sites to a designed shape. To apply
for clinical use, DNA nanostructures must meet several essential requirements, such as
they should remain intact after exposing to blood plasma, no immunogenicity. A major
challenge the DNA nanotechnology field facing now is the serum stability of DNA
nanoparticles, Although it was found that the rigid tetrahedron DNA structures(30),
compact DNA nanotubes(31) and DNA origami nano arrays(32) have improved nuclease
resistance, most DNA nanoparticles have a half- life. Although most DNA structures are
more stable at high Mg2+ concentration condition, such condition is not available in
vivo(33).
RNA nanotechnology is also a newly emerging field, with an evidence showing
that RNA nanoparticles can be assembled from bottom up assembly in 1998 (34), led by
Peixuan Guo. Dimer, trimer and hexamer pRNA nanoparticles were constructed using the
reengineered RNA fragment from phi29 DNA packaging motor packaging RNA, using
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the intermolecular interaction between two loops of each reengineered pRNA
molecule(34,35). This was an early proof of concept study for RNA nanotechnology.
The RNA nanotechnology field went into a rapid development phase after overcoming
the barricade of enzymatically and thermodynamically instability of RNAs by chemical
modifications. These include modification on bases such as 5-BrU and 5-IU (36),
modification on the phosphate linkage such as phosphothioate and boranophosphate (37),
modifications on the 2’-OH group with 2’-fluoro, 2’-o-methyl, 2’-amine (38-41), and
locked nucleic acid (42) which is modified by forming an extra bridge between 2’-O and
4’-C. 2’F pyrimidine modified RNA nanoparticles showed enhanced serum stability, the
2’F-pRNA 3WJ nanoparticles are stable in 50 % serum after 8 hours incubation at 37 °C
(43), in contrast, unmodified pRNA-3WJ are degraded in 50 % less than 1 h. LNA or
other chemical modification also greatly enhanced RNA particles enzymatically stability
substantially(4).RNA nanoparticles constructed with the modified RNA strands have
enhanced serum stability and also thermodynamical stability (44). The same pRNA-3WJ
structure

formed

by

2’F-pyrimidine

modified

RNA

strands

showed

higher

thermodynamic stability than unmodified RNA, following by DNA, which was verified
by as the dissociation constant (apparent KD) value for 2’F-RNA, RNA and DNA pRNA3WJ nanoparticles to be 4.5 nM, 11.4 nM and 47.7 nM respectively; as well as the
entropy value (ΔG°37) to be -36, -28 and -15 kcal/mol for 2’F-RNA, RNA and DNA
based pRNA-3WJ structure (44).
Several toolkits have been developed as principles for RNA nanoparticle
construction. The toolkit 1 utilized a biomimetic strategy learned from phi29 pRNA
hexamer structure, the hand in hand interaction between adjacent pRNA molecules. The
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pRNA folds into a complex structure including a helical ds-RNA domain with open 5’/3’
end and interlocking regions with two loops which was described as left hand and right
hand of pRNA. Interaction between the right hand and left hand loop from two pRNA
molecules promote a dimer formation(34,45,46). This mechanism has been utilized to
construct pRNA trimer, tetramer, pentamer and hexamer(47,48).
The toolkit2 utilizes palindrome sequence forming foot-to-foot interaction based higher
ordered RNA nanoparticles. A palindrome sequence reads the same from either 5’ end to
3’end direction or from 3’end to 5’end direction. Palindrome sequences can be added to
the end of helix domain of pRNA nanoparticles to form foot-to-foot dimer, foot-to-foot
trimer, foot-to-foot tetramer and so on(4).
The toolkit3 utilizes the highly thermodynamically stable pRNA-3WJ domain as a
core structure, and forming multivalent RNA nanoparticles by extension its arms. This
branched pRNA 3WJ nanoparticle have been shown to be able to carry three different
functional modules including fluorescent dye for in vivo tracking of nanoparticles, an
RNA aptamer for active targeting, and a siRNA or miRNA sequence for functional gene
expression modulation(43,49,49-52) . The similar principle was also extended to forming
a X-shaped motif which can carry four pieces of siRNA sequences and achieve
synergetic effect for gene knockdown(53).
Toolkit4 utilize more native tertiary RNA motifs to build varieties of three dimensional
RNA structures. The flexible pRNA-3WJ motif was utilized to construct two dimensional
RNA triangles, square, pentagon and hexagon structures (54,55), and even the three
dimensional RNA tetrahedron (56), prism (57) structure. Geary et al. design and
constructed an RNA sheet using 180° and 120° kissing-loop (KL) motifs from HIV-1
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DIS and RNAi/ii inverse loop (58), and dovetail motifs (59). A 2D hexagonal lattice
structure was created by connecting multiple tiles with kissing loop interactions. The
formed RNA structure called RNA origami can be folded during cotranscription without
request for annealing process. Nasalean et al. built an RNA filament structure by
assemble H-shaped RNA nanoparticle based on four way junction motif with loop-loop
interaction (60). Otherwise, similar strategy for DNA nanoparticle design such as using
Watson-Crick base paring and cross over can also be used for RNA nanostructures.
Toolkit 5 utilizes DNA/RNA hybrids to construct nanoparticles with functional
controlled release of fragment RNA (61). As the DNA and RNA have different
thermodynamic properties, which can be used to tune triggered dissociation of the
DNA/RNA hybrids (62-64).
RNA nanotechnology is getting more and more attention recently as they seem to
be the most appropriate carrier for functional RNA molecules, such as RNA aptamers
which can specifically bind to cancer cell marker for disease diagnosis and drug delivery
(43,65), siRNA and miRNA for RNAi therapy (66), or immune modulator CpG oligos for
immunotherapy (54). Intense studies on RNA nanotechnology for pharmaceutical
application are ongoing, including large scale production, and its immune modulation
properties, as well as its pharmacodynamics properties. MiRNA therapy includes miRNA
mimics and miRNA inhibitors. The miRNA inhibitors bind to a single stranded mature
miRNA to block its function, thus chemical modification on the anti-microRNA sequence
the hurdle of chemical and enzymatically stability can be solved. Substitution of the 2’OH group in the ribose ring with 2’-O-methyl, 2’-O-methoxyethyl, or 2’- fluoro groups
have shown increased the stability of anti-miRs (67). Successful delivery of LNA
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modified anti-miR21 seed sequence by RNA nanoparticles harboring EGFR targeting
aptamer showed promising result in regression of breast cancer in mice study(66). For the
miRNA mimics delivery, it is more challenging. The synthetic miRNA mimics must be
double stranded and processed into RNA induced silencing complex (RISC) to be
functional. Nanodelivery systems which can enhance its cancer cell targeted delivery, and
augment successful endosomal escape are important factors for miRNA therapeutics.
1.2 Aptamers and Nanotechnology
Aptamers are single stranded DNA or RNA oligonucleotides which can fold into
variety of complex secondary structures and thus bind to diverse targets including small
molecules, peptides, proteins and even whole cells with high affinity and specificity.
Aptamers are generated from an in vitro selection process called SELEX (Systematic
Evolution of Ligands by EXponential enrichment) (68). Aptamers mimics antibody in the
property of binding to target molecule with high affinity and specificity, while it exhibits
significant advantages in terms of its stability, ease of synthesis and its small size.
1.2.1 SELEX method
In vitro selection process, like finding a needle from a large haystack, starts with
construction of a large pool containing 1013 to 1016 random nucleic acid sequences
followed by iterative selection and amplification processes to get rid of the non-binding
sequences, while amplify and enrich the target binding sequences (Figure 1.1). The
selection process is usually monitored by the affinity of library to its target after each
round of selection. The end point of selection is usually marked with non-increasing
affinity of the library comparing to the previous round. The final round library is then
sequenced for aptamer identification.
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Figure 1.1. Schematic drawing shows the basic steps of SELEX. 1). A library contains
multiple sequences is constructed by in vitro transcription or chemical synthesis 2). The
library RNAs are subjected to binding reaction with the target molecule; 3). The mixture
of library and target complexes is then subjected to partition by method of selection; 4).
Remove the nonbinding sequences, the target binding sequences are then recovered and
amplified 5). Prepare library for next round of selection.
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The target for aptamer selection varies from small chemical entities such as
malachite green (69,70), 3, 5-difluoro-4-hydroxybenzylidene imidazolinone (DHFBI)
(71,72), to peptide, protein and cells. Through the invention of SELEX method in 1990s
by Tuerk and Gold (73), great efforts have been made to the methodology to improve its
success rate. One key step in SELEX process is the partition of the targeting binding
sequence from the non-binding sequences. To this end, nitrocellulose filter was used as
partition media to keep the protein bound nucleic acid sequences on the filer while
remove the non-binding sequences (74); later, functionalized magnetic beads were
developed as media to immobilize the target molecule thus recover the target binding
sequences on the beads(75). Considering the in silico folding of proteins might be
different from their folding when expressed on cell membrane, cell SELEX(76) and
tissue SELEX(77) were later adopted by scientists to find aptamers that can be directly
used clinically.
Another important step in SELEX process is sequencing. In traditional method the
last round library is usually cloned into vectors and single clones were randomly picked
up for Sanger sequencing (78). This step seems like trying one’s luck to get high affinity
aptamer. Recently, with the development of next generation sequencing technology, next
generation sequencing method has been utilized to aid SELEX (79,80). Millions of
sequences from amplified library can be analyzed at the mean time with deep sequencing
technique. The chance of finding an aptamer is increased by this method, which also can
be used to monitor the process of SELEX rather than a blinded operation.
To select an aptamer with high binding affinity to its target in vitro is usually not
the final goal for a SELEX project. A useful aptamer should be resistant to nuclease
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digestion, also can bind its target in vivo for application. To this end, large efforts have
been made, such as chemically modify the library during selection or the final aptamer
post selection to improve stability of the aptamer. Modification on both the sugar
phosphate backbone and the nucleobases of a RNA molecule can increase its stability,
and also expand its chemical functionality, increase the library diversity. Replacing the
phosphate-sugar backbone with phosphorothioate(81) or bridging the 2’-O and 4’-C of
the ribose forming locked nucleic acid (LNA) (82) can greatly increase the aptamer
stability against nuclease digestion(83). Examples of backbone modification on aptamers
include using 2’-amino-pyrimidines(84,85), 2’-Fluoro-pyrimidine(86,87), 2’-O-methyl
purine(88), Locked nucleic acids(89), 4’-thio-pyrimidine(90) or mixed modified
nucleotides(91) during in vitro transcription for library preparation. Y639F T7 RNA
polymerase can be used for most pyrimidine modified library preparation (83); KOD
Dash DNA polymerase can be used for LNA modified library preparation (89). 2’-Fluoro
pyrimidine modification is widely used for aptamer selection, the final VEGF aptamer on
market was selected using this protocol. But several 2’-amino pyrimidine modified RNA
aptamers are difficult to be synthesized in large scale thus they were abandoned from
therapeutic candidates (92). 2’-O-methyl is a common post transcriptional modification
on mRNA in nature, thus aptamer with 2’-O-methyl modification is easier to get
approved by FDA.
Modification on bases of RNA oligonucleotides can increase their enzymatically
stability, and also possibly enhance their catalytic functionality. It was reported that
incorporating an imidazole ring with nearly neutral pKa to library pool could enhance
their catalytic function (93). An RNA amide synthase was selected from RNA library
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including 5-imidizol uridine (94). Including 5’-bromo and 5’-iodo modified pyrimidine
into aptamer sequence can aid the UV crosslinking of aptamer to its target(83). 6aminohexyl adenosine was incorporated into RNA library during SELEX for ribozyme
selection (95).
Modification on the termini of an aptamer was also explored to increase its
stability and in vivo half life time (96). It was reported that capping the 3’end of
thrombin binding aptamer with locked nucleotides increased its stability against nuclease
in human serum (97). The incorporation of 2’4’-LNA to the 3’end of DNA aptamer was
achieved by terminal deoxynucleotidyl transferase (TdT)(98).
1.2.2 Aptamers for therapeutics
The first aptamer drug was approved by FDA in 2004, which is an RNA aptamer
against vascular endothelial growth factor (VEGF) -165 for wet age related macular
degeneration (AMD) treatment (99). This aptamer drug was developed targeting
VEGF165. By targeting VEGF165, the aptamer can block its interaction with VFGF
receptor presenting in eye blood vessels, and inhibit angiogenesis. Three separate SELEX
experiments were carried out in NeXstar Pharmaceuticals for its development (84,100).
The first unmodified RNA aptamer was isolated from a library with 30 random
nucleotides in 1994 (84). Subsequently, a 2’-NH2 pyrimidine modified RNA aptamer was
isolated and modified with 2’-O methyl on purine bases poste selection to increase its
nuclease resistance (100). Later, the 2’-F pyrimidine modified RNA aptamer was selected
with further improved affinity, the aptamer was modified with 2’-O methyl on purine
bases poste selection to enhance its nuclease resistance in vivo. The 2’-F pyrimidine, 2’-O
methyl RNA aptamer was selected for final drug development as Pegaptanib (100,101).
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Another aptamer targeting α-thrombin protein is being developed to an anti-coagulation
drug by blocking the interaction between fibrinogen and thrombin (102), which is under
phase II clinical trial by ARCA Biopharma Company (103).
The potential of using aptamer for immunotherapy has also been explored. DNA
aptamer-lipid probe was used to modify cell surface through noncovalent link for specific
cell targeting (104). This method can be used to engineer immune effector cells for
cancer therapy. DNA nanoscaffolds with double star shape or linear brunch shape
templated multivalent bispecific aptamer showed the ability to bridge two kinds of cell
specifically together (105). Oligonucleotide aptamers against immune modulation
proteins such as 4-1BB, CTLA-4 can also be developed as immune modulation drugs
(106).
1.2.3. Aptamers for targeted drug delivery
Besides being directly used as drugs, aptamers are also used as bullet for targeted
drug delivery. Targeted therapy can improve cancer treatment by increasing efficacy,
reducing toxicity and side effects. Aptamers have been widely used in targeted delivery
for chemotherapy and gene therapy. Two main types of aptamer modified drug delivery
systems are the aptamer nanomaterial conjugates and aptamers functionalized nucleic
acid nanoparticles (107).
Aptamers conjugated to varieties of nanoparticles can be used for targeted drug
delivery. Gold nanoparticles, silica nanoparticles, graphene or fullerene carbon based
nanoparticles have all been functionalized with aptamers for active targeting (104,107).
Multivalent aptamer decorated gold-silver nanorods can increase its target cell binding
affinity; can be potentially used for cellular imaging (108). Gold nanorods decorated with
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multiple prostate cancer targeting aptamers showed potential for targeted photo thermal
therapy targeting prostate cancer (109). Porous hollow magnetite nanoparticles decorated
with PEG functionalized with aptamer can load doxorubicin into the nanoparticles, and
direct nanoparticles to cancer cells through receptor mediated endocytosis, release drug in
the acidic lysosomal(110).
Aptamers fused to DNA or RNA nanoparticle can act as drug carriers by loading
chemotherapeutic agents through intercalation reaction (111), and nucleic acid based
therapeutics such as miRNA or siRNA through strand extension (52,66). But this should
be done without sacrificing the overall folding and affinity of both aptamer and the drug
conjugate (43,48,53).
1.2.4 Advantages and challenges for developing aptamer to drugs
There is significant advantage for using aptamers in diagnosis and disease
treatment. Aptamers are selected from an in vitro process without the request for animals,
and can be chemically synthesized which will ensure controllable quality assurance
comparing to the batch variations normally noticed in antibody production. One concern
of nucleic acid based aptamers for in vivo application is the stability. Its stability against
nuclease was greatly improved by using chemical modified RNA oligonucleotides to
instead of native nucleic acid. Modified RNA library can be prepared by substituting the
2’-OH group in pyrimidines with 2’-Fluoro, 2’-OH groups in purines with 2’-O methyl
groups (84,100). But there are still other challenges towards its clinical application. One
is the quick kidney elimination of aptamer after systemic administration, as the size of
aptamers usually falls in the range of less than 10nm and can be cleared by renal
glomerular filtration. Methods to increase the aptamer size are explored, including adding
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poly ethylene glycol (PEG) or cholesterol onto the RNA aptamers (112) to increase its
size thus the half life time in vivo. The toxicity of aptamer in vivo is not well studied yet,
although it is believed that protein free aptamers are less immunogenic than antibodies,
but Macugen has shown some side effects in AMD patient (112).
1.3 Extracellular Vesicles and drug delivery
Extracellular vesicles (EVs) are membrane surrounded particles secreted by
almost all cell types. EVs are also known as intercellular messenger organelles by
mediating intercellular communication and exchanging biological signals between cells.
EVs play important role in regulating both physiological and pathological process. The
following part will discuss about the biogenesis, the mechanism regulating EV releasing,
function of exosomes as well as their application for therapeutics delivery system.
1.3.1 Exosome biogenesis
EVs can be classified into three classes according to their biogenesis:
microvesicles, exosomes, and apoptotic bodies. Microvesicles are small membrane bound
fragments generated by outward budding from the plasma membrane. They have a very
heterogeneous population with size ranging from 100 to 1000 nm; while exosomes are
vesicles from the endosome membrane when multivesicle bodies fuse with the plasma
membrane at the end of endocytosis-recycling process (113), with size ranging from 50 to
140 nm. Exosomes are normally characterized by highly enriched tetraspanin proteins
including CD9, CD63, CD81 or CD82. They are proposed as exosome markers from
proteomic analyses (114). During the exosome biogenesis, the first step is formulation of
intraluminal vesicles following the inward budding of late endosome membranes. The
endosomal sorting complex required for transport (ESCRT) assembled into 4 complexes
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named ESCRT-0, 1, 2, 3 to capture and transport the sorted protein and other contents in
late endosome into ILVs. Both ESCRT dependent and independent mechanisms are
involved in the biogenesis of exosome (115). Protein TSG101 and Alix are certainly
involved in the ESCRT complex formation and exosome biogenesis; they are also
recognized as protein markers for exosomes (116).
1.3.2 Mechanisms regulating exosome release
Releasing of exosomes from donor cells is regulated by various conditions.
Savina et al. found that increasing intracellular Ca2+ concentration could stimulate
exosome secretion from a hematopoietic cell line K562, which was experimentally
proved that treating cells with monensin stimulated exosome release (117). Activating
cellular signals also can stimulate exosome secretion. Triggering CD40 /IL4 receptor in
murine B cells caused releasing high level of exosomes, although releasing exosome is
not a constitutive activity of B cells (118). Hypoxic condition also promotes exosome
release from cells. It was observed that culturing different breast cancer cell lines under
hypoxia condition or experimentally activation hypoxia signaling increased exosome
release (119). Riches et al. reported that exosome release is also affected by the presence
of exosomes in a feedback regulatory mechanism. Presence of exosomes in mammary
epithelial cells microenvironment could inhibit secretion of exosome from breast cancer
cells (120). Stimulating dendritic cells with HIV-1 virus also trigger release of exosomes,
which was found to be activated by stimulating the dendritic cell immune receptors(121).
1.3.3 Function of exosomes
Living cells communicate through multiple pathways. Direct cell interactions and
secreting soluble factors are two well-known methods for communication between cells.
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Releasing of membrane derived vesicles also named extracellular vesicles is a newly
discovered way for cellular communication. Extracellular vesicles were discovered in the
1980s by two independent labs during studying the fate of transferrin receptor in sheep
reticulocyte maturation (122) and pathway for transferrin receptor shedding (123). EVs
were later found play important roles in regulating normal physiological process(124),
such as stimulation of adaptive immune response(125), stem cell maintenance(126),
tissue repairing(127) and blood coagulation(128) in physiological conditions; and
promoting tumorigenesis (129), virus infection(130) and spread of amyloid-β-peptides
for Alzheimer’s disease development (131) in the pathological conditions.
EVs are natural vehicles for mRNA, miRNA, various noncoding RNA, genomic
DNA, and proteins delivering between cells (132). Various molecules including siRNA,
miRNA, mRNA and proteins are loaded into the lumen of EVs before its secretion (133).
Breast cancer cells derived exosomes are found contain miRNA and RNA-induced
silencing complex (RISC) for miRNA processing, thus promote tumorigenesis (134). As
intercellular communication organelles, exosomes may act as novel tools for disease
treatment

by

various

approaches,

including

(1)

immune

modulators

with

immunosuppressive or immune-activating effect or vaccination for multiple disease
treatment; (2) drug delivery vehicles for delivering proteins or nucleic acids to recipient
cells(135). These clues indicate the future of exosomes for therapeutic applications.
1.3.4 Application of Exosomes
Exosomes as gene delivery tools
Exosomes are natural carrier for various RNA molecules and proteins for cellular
communication. Delivery of exosomal RNA has significant effects in modulating the
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recipient cell phenotypes. Valadi et al. first reported that exosomes can transfer mRNA
and miRNA to recipient cells and the delivered RNA molecules are functional, can be
translated into proteins (136). The transfer of miRNA to recipient antigen presenting cells
can be directed by T cell derived CD63 positive exosomes, and its unidirectional (137).
EVs have been explored as delivery tools for various therapeutic agents, including
small RNA drugs, and chemotherapeutics (137). The most obvious advantage of using
exosomes as delivery vehicles for small RNA relies that they have natural homing ability
for small RNAs. The proteins and nucleoproteins including STAU1(double-stranded
RNA binding protein staufen homolog 1), STAU2, AGO2 (argonaute 2) and
TNRC6A(trinucleotide repeat containing gene 6A) associated with exosomes are
involved in RNA transport, processing(124). It was reported that exosomes isolated from
dendritic cells can deliver siRNA to mouse brain after systemic injection. The exosome
donor dendritic cells were reengineered to overexpress rabies virus glycoprotein (RVG)
peptide fusion to lysosome associated membrane glycoproteins (Lamp2b), thus the
isolated exosomes with neuron specific RVG peptide overexpression on its surface can
target brain cells. The re-engineered exosomes loaded with BACE1 siRNA targeting βsecretase (138) can deliver siRNA to wild type mice brain after systemic injection. It had
significant therapeutic effect on mice model shown as efficient mRNA and protein
knockdown(139). siRNA was loaded into exosomes by electroporation. Exosomes can
also transfer viral miRNA from the EBV-infected cells to the uninfected cells when they
are co-cultured, and the transferred miRNA was found to be functional (140). The GE
peptide positive exosomes from HEK293T cells can deliver let-7a miRNA to recipient
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EGFR positive breast cancer cells in vivo, and inhibited breast cancer development in
vivo(141).
Exosomes also fit for chemotherapeutics delivery. Comparing to artificial
nanovesicles such as liposomes and nanoparticles for chemotherapeutic delivery, EVs are
advantageous in their increased stability in vivo as for circulation, and decreased
immunogenicity and toxicity (142). The chemo resistance development in most tumor
disease is associated with the secretion of exosomes at low pH microenvironment in
tumor cells, and drugs such as cisplatin can be eliminated through exosome
releasing(143). But if using exosome as vehicles for drugs, it could protect drugs from
degradation, and enhance its cellular uptake can as increased uptake of exosomes was
also observed at low pH conditions (144). Exosomes are considered as promising
antitumor drug carriers (142). Chemical drug paclitaxel can be packaged into exosomes
and released into cell culture medium by treating mesenchymal stromal cells with
paclitaxel. The isolated paclitaxel loaded exosomes showed strong anti-proliferative
efficiency on pancreatic tumor cells in vitro (145). A recent study showed that
encapsulating paclitaxel into exosomes increased its cytotoxicity towards multi-drug
resistant cells around 50 times in vitro, high paclitaxel loading efficiency to exosomes
was achieved using a sonication method (146). Encapsulating doxorubicin into exosomes
did not increase its in vitro cytotoxicity on cancer cells, but it did reduce its cardiac
toxicity in xenograft mice model in vivo (147). All these studies showed that exosomes
are promising delivery systems for chemotherapeutics.
Exosomes as immune therapeutics
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Besides as gene therapy delivery vehicles, Exosomes are also developed as
immune modulatory therapeutics. Exosomes can generate CD8+ anti-tumor T cells
responses to maximize activation of specific T cells and enhance their anti-tumor
immunity. Tumor associated ascites-derived exosomes in combination with TLR3
agonists has been used as immunotherapy for ovarian cancer treatment in a clinical trial
(148). As tumor derived exosomes contain large amount of tumor associated antigens
(149), and MHC class I molecules for antigen presentation. Tumor derived exosomes also
showed vaccination effect for eradicating tumors in mice model (149).
Current questions to be solved for developing exosomes into immune therapeutic
includes: the method for preparation of GMP grade exosomes and to identify which
immune adjuvant to be used (148). One study showed that CpG adjuvants are proper
candidate for dendritic cells derived exosomes in vaccine therapy (150). Ascites-derived
exosomes in combination with the granulocyte macrophage colony stimulating factor
(GM-CSF) has been evaluated in phase 1 and phase 2 clinical trials for treating colorectal
cancer. Phase 1 clinical trial in 2008 with 40 patients concluded the ascites-derived
exosomes in combination with GM-CSF is feasible and safe (151). More exosome
related clinical trials on going are summarized in table 1(142).
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Table 1. Current exosomes based drugs under clinical trial
Disease

Exosome source

Melanoma,

Autologous monocyte
dendritic cell EVs, SC.

derived

UC
sucrose
cushion

Autologous monocyte
dendritic cell EVs, SC.

derived

CT1, n=15
Non-small
cell
lung
cancer,

Isolation

modification

Ref

MAGE3 loaded

(152)

Filtration/UC
sucrose
cushion

Peptide loaded

(153)

Autologous ascites derived EVs,
SC.

UC
sucrose
cushion

Unmodified
with
or w/o
GM-CSF

(154)

Plant nanovesicles

Filtration/UC

Curcumin,
exogenous
loading

NCT01294072

with

CT1, n=13
Colon cancer,
CT1, n=40
Colon cancer,
CT1, n=35
Type
diabetes,

I

Umbilical cord blood MSC-EVs

NCT02138331

CT1, n=20
Non-small
cell
lung
cancer,

Autologous
IFN-γ
matured
monocyte derived dendritic cell
EVs, intradermal

Ultrafiltration/
UC
sucrose
cushion

Peptide loaded

(155)

Chemotherapeu
tic
drugs,
exogenous
loading

NCT01854866

CT2, n=2
Malignant
pleural
effusion,

Tumor cell derived microparticles
as vector for chemotherapeutics
drug delivery

CT2, n=30
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1.3.5 Prospective
Although the study on exosomes is still in its young stage, exosomes already
showed great advantage in solving some difficult questions in drug delivery field.
Exosomes can cross the blood brain barrier, can be engineered to achieve specific
targeting effect, can bypath the endosome trapping for RNAi drug delivery as naturally
evolved functional machinery in cells. Although there is challenge towards the clinical
application, such as the above motioned yield and GMP production difficulty, and also
unknown immunogenicity towards the recipient in long term. Hopefully great promise
will be made in the future.

Copyright © Fengmei Pi 2016
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Chapter 2: Development of High-Affinity Thermo-Stable Divalent RNA
Antibody for Cancer Cell Targeting and Delivery
This chapter (with some modification) is under preparation. Special thanks to Dr.
Ashwani Sharma for help and assistance in preparation of data for Figure 2.S1.
ABSTRACT:
Widely used protein antibody contains two binding sites providing immense biomedical
applications with high affinity and specificity. RNA aptamers expanded the field of
antibodies, but have low specificity which is partly attributed to their monovalent nature
thus limiting their biomedical application. Divalent aptamers fusing two aptamers into a
single unit have been reported but such fusion causes refolding and structure alteration
affecting their affinity and specificity. Inspired by nature and using state-of-art RNA
nanotechnology platform, we report here a novel divalent RNA antibody (RNA-Ab)
design utilizing unusual thermodynamic stability of the pRNA three-way junction (3WJ)
of phi29 DNA packaging motor. The highly stable 3WJ provides a rigid core to the RNA
architecture similar to antibodies keeping both the loops separated for independent target
binding, and further disfavor misfolding of RNA-Ab when conjugated to oligonucleotide
therapeutics, keeping affinity and functions of attached functionalities intact. Using this
3WJ based nanotechnology design; we describe the selection and characterization of
serum and thermodynamically stable divalent RNA-Ab against a prominent cancer
marker EpCAM with high affinity and specificity
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INTRODUCTION:
RNA nanotechnology is a rapidly growing field, which involves the programmable and
addressable designs of RNA 3D architectures. A large number of highly ordered RNA
structures including triangles (54), square (55), pentamers (54), hexamers (47,48) and
boiling resistant hexacubic arrays (156) have been constructed and shown to perform
diverse biological functions. Recently, our lab has discovered unusually stable three-way
junction (3WJ) motif of pRNA that assembles with high affinity from three different
RNA strands and is resistant to denaturation by 8 M urea (43). Utilizing this highly stable
3WJ motif as core, several nanostructures harboring different functional modules such as
RNA aptamers, ribozymes, siRNA etc. have been constructed which are shown to retain
their folding and functionality for specific cell binding (43,53), catalytic activity (43),
gene silencing (53,157), and fluorogenic properties (72,158)both in vitro or in animal
models.
MATERIALS AND METHODS:
Cell lines
HT29, HCT116, KB cells, CD4+ Jurkat cells, and MDA-MB-231 cells were
purchased from American Type Culture Collection (ATCC). KM-20 cells were
generously provided by Dr. Piotr Rychohou (University of Kentucky, USA). All cell
lines were maintained in water jacketed CO2 incubator at 37 °C with 5 % CO2. KB cell
and CD4+ Jurkat cells were cultured in RPMI1640 medium supplemented with 10% fetal
bovine serum (FBS, Hyclone). HT-29 and HCT-116 cells were cultured in McCoy’s 5A
medium supplemented with 10 % FBS. KM-20 cells were cultured in MEM medium
supplemented with 10 % FBS, 10 ml/L of sodium pyruvate, 10 ml/L non-essential amino
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acid, 20 mL/L of MEM essential vitamin mixture. MDA-MB-231 cells were cultured in
DMEM medium supplemented with 10 % FBS, MCF-7 cells were cultured in EMEM
medium supplemented with 10 % FBS and 1 % of bovine insulin.
Library builds up
The 116 nt DNA library with 60 random bases was chemically synthesized in one
micromole scale from (W. M. Keck Oligonucleotide synthesis Facility, Yale University).
The sequence of ssDNA library (Figure 2.S1) consist two random regions that are
flanked by known primer-binding regions and a conserved middle region which can fold
with the primer binding region to form the complete 3WJ assembly. The ssDNA library
was PCR amplified with primers L6F1 and L6R1 to generate the double-stranded DNA
template. The dsDNA was then in vitro transcribed to 2’Fluoro pyrimidine modified
RNA library using Y639F T7 polymerase for selection process. To maintain the diversity
of the library, 30 pmol of DNA (2×1013 sequences) was amplified in a 10ml PCR
reaction. The PCR products were purified by MinElute PCR purification kit (Qiagen) to
remove the primers and free nucleotides. The purified dsDNA library (5 µg) was in vitro
transcribed into initial 2’-fluoro-pyrimidine modified RNA library in a 100 µL reaction,
treated with DNaseI and used directly for in vitro selection.
ssDNA libraryDNA: 5’- GGA GGC ACC ACG GCT GGA TCC GGA TCA ATC ATG
GCA A-N30- T TGC CAT GTG TAT GTG GG-N30- CCC ACA TAC TTT GTT GAT
CCT TGG TCA TTA GGA TCG-3’
L6F1DNA: 5’-GTA TAA TAC GAC TCA CTA TAG GG C CGG ATC AAT CAT GGC
AA3’
L6R1DNA: 5’-GGA TCA ACA AAG TAT GTG G3’
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Sph1-L6R1DNA: 5’- CTC CCG GCC GCC ATG GCC GCG GGA TTG GAT CAA
CAA AGT ATG TGG-3’
Cy5-Sph1 DNA: 5’-Cy5/CTC CCG GCC GCC ATG GCC GCG GGA TT-3’
LNA21-Sph1: 5’ +G+A+T+A+A+G+C+TCTCCCGGCCGCCATGGCCGCGGGAT-3’
3WJa-Sph12’F RNA: 5’-uuG ccA uGu GuA uGu GGG AAu ccc GcG Gcc AuG Gcc
GGG AG-3’
3WJa 2’F RNA: 5’- uuG ccA uGu GuA uGu GGG-3’
3WJb 2’F RNA: 5’-ccc AcA uAc uuu Guu GAu cc-3’
3WJc 2’F RNA: 5’-GGA ucA Auc AuG GcA A-3’
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Figure 2.S1. Primary sequence of bivalent RNA nanoparticle library. The library
contains two random regions for target binding selection and a pRNA-3WJ scaffold
providing a rigid Y shaped structure mimicking antibody.
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Protein immobilization
The extracellular fragment of EpCAM protein (Met1-Lys265) with poly histidine
at its C terminal was purchased from Sino Biological Inc. 5µg of His-tagged EpCAM
protein was immobilized to 3 µL of dynabeads® his-tag isolation (Invitrogen) in 100 µL
of binding buffer at 4 °C overnight following the manufacturers protocol. A polyHistidine peptide was immobilized to magnetic beads following the same procedure for
negative selection.
In vitro selection
20 µg of 2’F-RNA library was first incubated with 3 µL of His-peptide
immobilized dynabeads as negative selection to remove non-specific binding sequences.
20 µg of yeast tRNA was added in the binding buffer to reduce non-specific reaction.
This RNA library taken from supernatant of negative selection tube was then incubated
with 5 µg of EpCAM protein immobilized magnetic beads with yeast tRNA in SHMCK
buffer (110 mM NaCl, 20 mM HEPES, 1 mM MgCl2, 1 mM CaCl2, 5 mM KCl, pH 7.4)
at room temperature for 3 h as positive selection. The beads were washed 3 times with
SHMCK buffer after incubation. The target-bound RNA sequences on magnetic beads
were directly reverse transcribed into DNA by ThermoscriptTM Reverse transcriptase
(Invitrogen), followed by PCR amplification. Then 2’-F RNA was generated by in vitro
transcription for next round of SELEX. During the SELEX process, the protein
concentration, incubation times were decreased gradually or the washing time was
increased gradually to increase the stringency of selection to acquire aptamer with high
affinity.
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The enriched library after 7 to 9 rounds of SELEX process was reverse
transcribed, PCR amplified for 7 cycles with Taq polymerase (Promega) and agarose gel
purified, cloned into the pGEMT vector plasmid (Promega). Plasmid DNAs from the
selected individual clones were extracted from E Coli cells with Genejet plasmid
purification kit (Fermentas), and sequenced by Advanced Gene Technology Center
(University of Kentucky). The aptamer sequences were analyzed with Cluster W2(159),
random regions were aligned using MultAlin (160) and secondary structures were
predicted using M-Fold software (161).
Flow cytometry analysis
Plasmid DNA from clones were PCR amplified with primer L6F1 and sph1-L6R1
to extend its 3’end with extra 26 nucleotides for fluorescent labeling. 2’F RNA was in
vitro transcribed and purified from 8 M urea, 8% polyacrylamide gel by crush and soak
method, followed by ethanol precipitation. To label the 2’F RNA with Cy5 fluorescent
dye, a 5’-Cy5 modified DNA oligo Cy5-Sph1 (IDT) complimentary to the extended
3`end region of corresponding 2’F RNA sequence was hybridized by heating at 80°C for
5 min and step cool down to 4 °C.
Cells cultured in T-75 flask were harvested with 0.25 % trypsin. Around 2 × 105
cells were incubated with different concentration of Cy5 labeled 2’F RNA nanoparticles
in OptiMEM medium for 1 h at 37 °C, protect from light. Cells were then washed three
times and suspended in PBS for analysis by flow cytometry.
Confocal microscopy method
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Cells were grown in cover glass (Fisher Scientific) in 24 well bottom culture
dishes in its complete medium overnight. On the day of testing, cells were washed with
OptiMEM medium twice, incubated with Cy5 labeled 2’F RNA nanoparticles at 37 °C
for 1 hr. After that cells were washed with PBS twice, fixed with 4% paraformaldehyde
(Microscopy Sciences) in PBS at room temperature for 20min; then washed with PBS
and permeabilized with 0.05 % Triton X100 in PBS at room temperature for 3 min; the
cells were stained with Alexa488 Phallodin (Invitrogen) at room temperature for 20 min
and washed with PBS, air dried. Cell nucleus was stained with DAPI gold anti fade
(Invitrogen) for confocal microscopy imaging with FluoView FV 1000-Filter Confocal
Microscopy System (Olympus) (Available from University of Kentucky, Markey cancer
center) .
Inhibition of endocytosis
The inhibition of endocytosis assay was carried out as described before (87)，
briefly pretreat cells in a potassium depletion buffer (50 mM HEPES, 140 mM NaCl, 2.5
mM MgCl2, and 1 mM CaCl2) or in a hypertonic buffer (potassium depleted buffer plus 3
mM KCl and 450 mM sucrose) at 37 °C for 1 hr, then incubate cells with the RNA
nanoparticles for test. The cells were treated the same way as for confocal microscopy
assay. Potassium depletion buffer or hypertonic buffer was used for the following wash
steps.
Design and construction of EpCAM RNA Ab harboring anti-miR21
The locked nucleic acid (LNA) modified oligonucleotides targeting the seed
sequence of microRNA 21 (miR21)(66,162) was tested as model nucleic acid

34

therapeutics for A9-8 RNA-Ab mediated delivery effect. A 26 nucleotide (nt) sequence
named sph1 was added to the 3’end of 7 nt LNAs for nanoparticle assembly, named
LNA21-Sph1. The LNA21-Sph1 was synthesized by EXION Company. The A9-8
harboring LNA oligo nanoparticle was prepared by hybridizing LNA21-sph1 to A9-8Sph1 2’F-RNA by heating to 80 °C for 5 min and step cool down to 4 °C. Control
nanoparticle harboring anti-miR21 was prepared by hybridizing 3WJa-sph1 2’F-RNA
with LNA21-sph1 at 80 °C for 5 min and step cool down to 4 °C, then mix with 3WJb
2’F-RNA and 3WJc 2’F-RNA at equal molar ratio at room temperature.
Dual luciferase assay to analyze delivery of anti-miR21 by A9-8
Cells were seeded in 24 well plates in its complete medium at density of 2 × 105
cells/mL. PsiCheckTM-2 plasmid which contains miR21 seed sequence at 3’-UTR region
of Renilla Luciferase reporter gene was constructed (Promega) (66,162). The plasmid
was transfected to cells with Lipofectamine 2000 (Life technologies). Four hours post
transfection the cell medium was changed to complete growth medium and incubated for
another 2 h. Then the nanoparticles diluted in 200 µL of serum free medium were added,
4 h later complete medium was added. The cells were lysed after 24 h and test for
Luciferase and Renilla expression by dual luciferase assay system (Promega). At least
three biological repeats were performed.
RESULTS AND DISCUSSION:
RNA aptamers have been extensively investigated since 1990 (163). They are of
significant utility for targeted delivery of oligonucleotide therapeutics because of their
ability to bind specifically to different protein targets. However, there are still challenges
towards its medical application. One challenge especially for targeted therapeutics
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delivery is their low affinity for substrate interaction (164), which might be caused by its
monovalent nature, or misfolding of aptamer-conjugates which sacrifice function of both
aptamer and attached oligonucleotide therapeutics conjugate such as siRNA or miRNA.
Another challenge is rapid clearance of RNA aptamer from circulation which is attributed
to their relatively small size (165). Significant efforts have been done in recent past to
overcome these limitations. To enhance the affinity of aptamer, Muller et al.(166) were
the first to demonstrate a multivalent approach by linking together two aptamers that bind
to distinct epitopes on thrombin protein through a poly (A) linker and showed
improvement on afﬁnity over the monovalent aptamer. To reduce renal clearance of
aptamers, adding significant mass by linking aptamer end to polyethylene glycol
(PEG)(101), to streptavidin via 3`biotin and by attaching Fc tail of IgG has been shown
promising results (167). To overcome the folding problem Berezhnoy et al.(168) has
recently reported that fusing siRNA with lower melting temperature to 3`end of aptamer
has minimal effect on overall folding of the aptamer conjugate.
These literature findings emphasize the need of a novel scaffold which can
increase aptamer target binding affinity by its multivalence, increases its size to enhance
its bioavailability in vivo, and can be directly conjugated with oligonucleotide therapeutic
without interrupting the folding of both parties. To meet these requires, we propose here a
novel divalent RNA-Ab design based on thermodynamically stable antibody shaped
pRNA-3WJ motif (26,43) for RNA based andibody development (Figure 2.1). The
design utilizes the highly stable three way junction (3WJ) motif of phi29 DNA packaging
motor pRNA which provides a rigid core structure similar to constant region of
antibodies, allowing both loops to fold independently. Moreover, the 3WJ core adds

36

significant size to RNA antibody nanoparticle to disfavor renal clearance (169) and
provides a handle to attach variety of drugs or therapeutic oligonucleotides like miRNA
and siRNA without attenuating RNA-Ab`s activity or specificity. The design is generally
applicable for in vitro selection of RNA-Ab virtually against any target, and can be
advantageous in the development of RNAi based therapeutics or sensing platforms.
Using this design, we generated a nuclease resistant RNA-Ab against the cancer
stem cell marker epithelial cell adhesion molecule (EpCAM), a transmembrane protein
overexpressed in many cancer cells including stem cells. The selected RNA-Ab
specifically binds to cancer cells overexpressing EpCAM with low KD in nM range for
different cell lines. Both RNA-Ab loops participate in binding and RNA-Ab was further
shown to deliver anti-miR21 to breast and colon cancer cells.
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Figure 2.1. Physiochemical and biological properties of the bivalent RNA antibody. a.
RNA-Ab design based on 3WJ crystal structure with two random loop sequences
conjugate to 3WJ core motif of phi29 pRNA(43) b. A crystal structure of an intact
monoclonal antibody for phenobarbital (PDB ID: 1IGY), c. DLS measurement of size
distribution and d. zeta potential of selected RNA-Ab. e. Representation of a typical flow
cytometry binding analysis comparison of Cy5 Labeled sequences to EpCAM positive
MCF-7 cells. Gray represnts cell only, blue control aptamer sequence (50 nM) and red
RNA-Ab A9-8 (50 nM).
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To select a protein antibody shaped RNA aptamer (Figure 2.1), the
thermodynamically stable pRNA-3WJ core was used as the constant region. Two random
sequences were placed to the two arms of the 3WJ, mimicking two heavy chains of
protein antibody serving as the two variable regions. The two random loops on either side
of the 3WJ will provide bivalency and thus strong specificity to the target. Moreover, the
thermodynamically stable 3WJ core will help maintain independent folding of each loop,
providing overall stability. This design is advantageous since the third arm mimics the Fc
complement binding domain on protein antibodies, thus can be attached with various
therapeutic functionalities such as siRNA or miRNA without any detrimental effect on
the folding of either RNA-Ab or the attached functionality. 2’-fluoro pyrimidines
modified RNA library was used to enhance the serum stability of the RNA-Ab.
Epithelial cell adhesion molecule (EpCAM) was chosen as the target that is highly
expressed on the most malignant epithelial cancers. In normal epithelia, EpCAM is only
expressed on basolateral gap junctions, thus not accessible to various antibodies or drugs
while in epithelial cancers, it is distributed homogenously on cell surface (170). Studies
have revealed the importance of EpCAM in cancer biology, including processing of cell
migration, cell proliferation (171), cancer cell invasion and metastasis (172). EpCAM
protein is rapidly internalized when it is bound to antibodies, thus the RNA antibody
against EpCAM will suit for payloads delivery by receptor-mediated endocytosis (173).
To select an RNA-Ab against EpCAM protein, we used magnetic beads based
SELEX protocol as discussed above. An initial 2’-F RNA library containing 2×1013
species was incubated with the EpCAM attached magnetic beads for first round SELEX.
A total of nine rounds of selection against EpCAM recombinant protein were carried out.
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The negative selections were introduced in the first and seventh rounds. For negative
selection, RNA library was passed through only His 6- peptide attached to magnetic
beads. A total of 9 rounds of selection were performed and the selective pressure was
stepwise modified by decreasing target concentration and incubation time. The progress
of the selection was determined by filer binding assay(174). The selection rounds showed
enrichment in filter binding assay till 8th rounds and thus selection process was stopped
after performing an extra round at 37 °C to get the highest binding sequence at biological
temperature. The last round library was cloned into pGEM-T vector and 20 clones were
sequenced and analysed for their secondary structure predictions. The data showed some
repeating sequences (Figure. 2.S2a). Three different sequences were chosen based on
their secondary structures (using M-fold (161)) or number of repeats and were tested for
their cell binding ability using flow cytometry (Figure. 2.S2b). The clone A9-8 now on
referred as RNA-Ab showed the best results for cell binding in flow cytometry (Figure
2.S3) and was chosen for further studies.
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Figure 2.S2. Sequence alignment and secondary structure analysis to identify final
RNA-Ab. a. Sequence alignment of picked clones after 7th and 9th round of SELEX
using MultiAlin. A9-8 in 9th round library reserved all 3WJ sequences, and A7-2, A7-10
showed multiple repeats were chosen for further analysis. B. Secondary structure A9-8,
A7-2, A7-10 calculated by M-fold.
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Figure 2.S3. Comparing the binding affinity of selected 3 sequences with MCF7
cells in vitro. a. Sequence A9-8 showed an apparent KD of 9.90 nM to MCF7 cells, b.
Sequence A7-2 showed an apparent KD of 25.58 nM to MCF7 cells, c. Sequence A7-10
showed an apparent KD of 32.37 nM to MCF7 cells in flow cytometry analysis. d.
Comparing the binding of 3 sequences to MCF7 cells at the concentration of 50 nM by
flow cytometry. The result is consistent with apparent KD test, A9-8 showed the strongest
binding affinity among the three sequences.
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Generally, nanoparticles with a size of 10-100 nm are optimal for drug delivery
due to slow renal clearance and improved in vivo circulation time avoiding liver and
spleen cleaning up (175). We determined the nanoparticle size distribution of selected
RNA-Ab against EpCAM protein using dynamic light scattering with Malvern Nanosizer.
RNA-Ab showed a mean size of 14.25 ±0.05 nm as shown in Figure 2.1. The 3WJ
structural core motif adds significant size and mass to bring it to optimal nm size range
for slow renal clearance, and thus consequently high tumour localization is anticipated as
previously shown by 3WJ constructs(169).
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The binding affinities of selected RNA-Ab A9-8 with different EpCAM positive
cell lines were determined by flow cytometry with cy5-labeling. Breast cancer cell lines
MCF-7(87,176), MDA-MB-231(87) and colon cancer cell lines HT-29 (87,177), HCT116 (178) and KM-20 were tested as EpCAM positive cell lines; Jurkat cell line(179),
which does not express EpCAM was tested as negative cell line. The cells were incubated
with varying concentration of RNA-Ab or the control scramble sequence, and the binding
of RNA-Ab to EpCAM positive cells was observed as shown in a typical histogram in
Figure 2.1d. RNA-Ab A9-8 binds significantly higher to EpCAM positive cell MCF7
than control 3WJ 2’F RNA nanoparticle, which was assembled by mixing equal molar
ratio of 3WJa, 3WJb, and 3WJc 2’F RNA. The normalized bound cell ratio against
aptamer concentration was plotted in a graph and fitted to one site specific binding curve
to determine the apparent dissociation constants (KD) of RNA-Ab with different cell lines
as shown in Figure 2.2. The nonspecific binding from control sequence to cells was
subtracted for KD analysis. The data shows that RNA-Ab binds specifically to different
EpCAM positive cell lines with apparent KD values in nM range and showed non-specific
binding to EpCAM negative Jurkat cells as represented by a linear binding curve (Figure
2.2f). RNA-Ab showed the highest binding affinity at KD of 9.90 ± 2.15 nM (Figure.
2.2d) to human breast cancer cells line MCF7.
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a.

b.

c.

d.

e.

f.

Figure 2.2. Determination of apparent dissociation constants (KD) of RNA-Ab with
cells. The binding curves for RNA-Ab with EpCAM positive cell lines (a-e) and negative
cell line (f). The straight line in ‘F’ represents non-specific binding and thus very high KD
values ( > 200 nM).
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The specific cell binding and entry of RNA-Ab A9-8 to EpCAM positive cells
was further confirmed by confocal microscopy showing cellular distribution. The RNAAb A9-8 gets internalized into the cells through receptor-mediated endocytosis and thus
does not require any transfection reagent. Moreover RNA-Ab A9-8 specifically bind to
EpCAM positive breast cancer cell lines MCF-7 as well as colon cancer cell lines HT-29
and HCT-116, whereas no binding was observed for EpCAM negative Jurkat cells
(Figure 2.3). The magnified view of cells shows that the Cy5-labeled RNA-Ab was
localized in the cell cytoplasm, whereas under similar conditions the control sequence
showed very low binding. To test whether RNA-Ab A9-8 can be internalized to cell
cytoplasm following binding, the receptor mediated endocytosis pathway was blocked by
treating MCF-7 cells under potassium depletion condition (87). Incubating Cy5-labeled
RNA-Ab with the MCF-7 cells that pre-treated with potassium depletion buffer, the
RNA-Ab did not enter into the cell cytoplasm but rather bound only to the cell membrane
forming a circle around the cell membrane (Figure 2.3a). In contrast, incubating RNAAb under normal condition with MCF-7 cells, it gets internalized and distributed as
shown by dispersed dots near cell nucleus. Thus, it can be concluded that the RNA-Ab
gets internalized into the cells after binding to receptors on the cell surface membrane.
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Figure 2.3. The cell entry of RNA-Ab tested by confocal microscopy. a. The binding
and subcellular distribution of RNA-Ab to EpCAM-positive cancer cell lines (MCF-7,
HT-29, and HCT-116) and to EpCAM negative cell line (Jurkat) b. Binding and
subcellular distribution of RNA-Ab and control sequence to EpCAM positive cell line
MCF-7 in potassium depletion buffer when receptor mediated endocytosis pathway is
blocked and in normal conditions.
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To investigate whether both loops of the RNA-Ab participate in binding to the
target mimicking a protein antibody, we truncated RNA-Ab by deleting one loop at a
time, keeping the other loop intact. This provided two new aptamer structures as shown
in Figure 2.4. Next, the binding affinity of these one-loop structures towards MCF-7
cells were tested by flow cytometry, the original RNA-Ab was tested as positive control.
The structure with only loop 1 showed an apparent KD around 25 nM (Figure 2.4a) while
the structure with only loop 2 showed a KD around 15 nM (Figure 2.4b), whereas the
original RNA-Ab with both the loops present have a KD value of around 9.9 nM (Figure
2.4c). This shows that both the loops in RNA-Ab bind to its target with high affinity
proving bivalent nature of selected RNA antibody. We also tested the binding affinity of
recently reported 2’F-RNA aptamer EpDT3 to MCF-7 cells (87), which is the only 2`FRNA aptamer selected so far against EpCAM. All the loop deleted structures and the full
length RNA-Ab showed lower apparent KD than EpDT3 which showed apparent KD
value around 83 nM to MCF7 cells in our experiment (Figure.2.4d).
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Figure 2.4. Determination of apparent dissociation constants (KD) for loop deleted
RNA-Ab with EpCAM positive MCF7 Cells. a. Loop1 deleted RNA-Ab, b. loop 2
deleted RNA-Ab, c. the full length RNA–Ab, and d. the reported 2’F-RNA aptamer for
EpCAM binding affinity comparison
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Micro-RNA 21 (miR21) was discovered as an oncogenic miR which targets a
number of tumour suppressor genes (180,181). High level expression of miR21 is
associated with various types of cancers. A 8-mer tiny locked nucleic acid (LNA), which
is complementary to the seed sequence of miR21, has been reported to be able to knock
down the miR21 expression, and inhibit the microRNA 21 function in vitro and in vivo
(162). EpCAM protein has been previously shown to act as a cargo to internalize the
attached payloads (173). To investigate if the newly developed RNA-Ab A9-8 can
specifically deliver anti-miRNA oligonucleotide into EpCAM positive cells, a dual
luciferase reporter assay system was used to detect the miR21 level in cells. The perfectmatch anti-miR21 sequences were cloned to 3’UTR region of the primary reporter gene
Renilla luciferase. The second reporter gene Firefly luciferase was used as internal
controls, which allows normalization of the Renilla luciferase expression for endpoint
lytic assays. RNA-Ab constructs harbouring anti-miR21-LNA were prepared by
hybridizing the LNA oligonucleotide (LNA21-Sph1, Figure 2.5a) to the 3’-end extended
RNA-Ab. RNA 3WJ nanoparticles harbouring anti-miR21-LNA were constructed as
negative control. EpCAM positive breast cancer cell line MCF-7 and colon cancer cell
line HCT-116 have high level of miR21 expression (data not shown here). After
incubating RNA-Ab miRNA construct with cells, A9-8-LNA significantly reduced
miR21 level in cancer cells with a dose depending response. In contrast the 3WJ-LNA,
LNA itself, or RNA-Ab did not knockdown the miR21 levels (Figure 2.5b, c). Results
showed that RNA-Ab A9-8-LNA can deliver its cargo anti-miRNA into cell cytoplasm
and significantly knockdown miRNA expression level.

50

Figure 2.5. RNA-Ab mediated delivery of anti-miRNA21 to EpCAM positive cancer
cells. a. The secondary structure of A9-8-LNA nanoparticle, which is assembled from
two pieces of oligonucleotides. b. Delivery of anti-miR21 to MCF-7 cells by incubating
cells with different concentration of nanoparticles. c. Delivery of anti-miR21 to HCT-116
cells by incubating nanoparticles with cells. RLU is relative Renilla to firefly luciferase
unit, which is reversely related to miR21 levels in cells.
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CONCLUSION:
In conclusion, the divalent RNA antibody presented here binds its target with high
affinity and specificity. The key design feature of the RNA-Ab is highly stable 3WJ core
derived from phi29 packaging motor, which provides significant mass and helps to
maintain folding of attached oligonucleotide therapeutics for efficient delivery. The
design can be used for selection of RNA antibody virtually against any small molecule or
protein. Further experiments are underway to show its therapeutic utility in animal
models. Although several antibody based immunotherapeutic targeting to various cancer
biomarkers have been developed, they suffer from instability, lack of proficient clinical
response and discrepancy in quality of antibodies from batch to batch (170). Moreover,
the effect of antibody dependent cell mediated cytotoxicity (ADCC), antibody-mediated
complement dependent cytotoxicity (CDC) and induction of anti-idiotypic response
critically rely on the carbohydrate composition in the CH2 domain of the antibodies,
which can vary largely in batches (170). The RNA-Ab design presented here can be
chemically synthesized. It is anticipated to provide improved oligonucleotide therapeutic
delivery for various diseases to provide better healthcare.
ACKNOWLEDGMENT:
The authors would like to thank Ashwani Sharma, Yi Shu, and Dan shu for help
with the experimental designs. The work was supported by NIH grants EB012135 and
EB003730 and funding to Peixuan Guo’s Endowed Chair in Nanobiotechnology position
from the William Fairish Endowment Fund. The content is solely the responsibility of the
authors and does not necessarily represent the official views of NIH.
Copyright © Fengmei Pi 2016
52

Chapter 3: Nanoparticle Orientation to Control RNA Loading or
Surface Display of Extracellular Vesicles for Efficient Cell Targeting,
siRNA Delivery and Cancer Regression
This chapter (with some modification) is under revision at Nature Nanotechnology.
Special thanks to Dr. Daniel Binzel and for help and assistance in assays with prostate
cancer cells in vitro and Hui Li, Dr. Bin Guo for help and assistance with in vivo assays.
INTRODUCTION:
It has been popularly believed that the advantage of nanotechnologies is the top-down
and bottom-up construction approaches to make particles in nanometer-scale holding
unique and special function. Here we report one more advantage of nanotechnology by
controlling the structural orientation to regulate the anchoring of nanoparticles on
extracellular vesicles (EVs) membrane for specific cancer targeting and intracellular
trafficking. The orientation of arrow shaped RNA nanoparticles on EVs was possible to
be controlled. Placing a membrane anchoring cholesterol at the arrow tail resulted in
displaying of RNA aptamer or folate ligand onto the surface of EVs. In contrast, placing
the chemical at the arrow head resulted in partial loading of RNA nanoparticles into the
EVs. Taking advantage of the RNA aptamer ligand for specific targeting and EVs for
efficient membrane fusion, the resulting RNA aptamer-displaying EVs were used for
specific delivery of siRNA with efficient gene silencing resulting in complete blockage of
cancer growth. Animal studies showed that the nanometer scale ligand-displaying EVs
specifically localized in tumor xenografts without accumulating in healthy organs.
Efficient gene silencing was observed both in cell culture and animal trials from systemic
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administration of PSMA (Prostate Membrane Specific Antigen) aptamer-displaying EVs
loaded with survivin siRNA.
MATERIALS AND METHODS:
The construction, synthesis and purification of RNA nanoparticles with or without
the 2'F modification or Alex647 labeling has be reported (43).
The PSMAapt/3WJ/Cholesterol RNA nanoparticle was assembled by mixing equal
molar ratio of three RNA oligo strands including a3WJ-Cholesterol, b3WJ-Alexa647 and
c3WJ-PSMAapt 2’-F RNA in TES buffer (50 mM Tris, pH8, 5 mM EDTA, 0.05 M NaCl),
heating to 85 °C for 5 min, then slowly cooling down to 4 °C. The assembly of RNA
nanoparticles was detected in 8 % TBM-Polyacrylamide gel. The sequences of all the
RNA strands (lower case letters indicate 2'-F nucleotides) are:
(1)

a3WJ: 5’-uuG ccA uGu GuA uGu GGG-3’

(2)

a3WJ-sph1: 5’-uuG ccA uGu GuA uGu GGG AAu ccc GcG Gcc AuG Gcc GGG
AG-3’

(3)

a3WJ-survivin sense: 5’-uuG ccA uGu GuA uGu GGG GcA GGu uCC uuA ucu
Guc Auu-3’

(4)

a3WJ-survivin sense(scramble): 5’-uuG ccA uGu GuA uGu GGG AAu ccc GcG
Gcc AuG Gcc GGG AG-3’

(5)

a3WJ-Folate: 5’-(Folate)uuG ccA uGu GuA uGu GGG -3’ (custom ordered from
Trilink)
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(6)

a3WJ-Cholesterol: 5’- uuG ccA uGu GuA uGu GGG(Cholesterol TEG)-3’ (custom
ordered from Trilink)

(7)

b3WJ: 5’-ccc AcA uAc uuu Guu GAu ccc-3’

(8)

b3WJ-Folate: 5’-(Folate)ccc AcA uAc uuu Guu GAu ccc-3’

(9)

b3WJ-Cholesterol: 5’-ccc AcA uAc uuu Guu GAu ccc(Cholesterol TEG)-3’
(custom ordered from Trilink)

(10) b3WJ-Alexa647: 5’-(Alexa647)(AmC6)- ccc AcA uAc uuu Guu GAu ccc-3’
(custom ordered from Trilink)
(11) c3WJ: 5’-GGA ucA Auc AuG GcA A-3’
(12) c3WJ-PSMAapt: 5’-GGA ucA Auc AuG GcA AuG GGA ccG AAA AAG Acc uGA
cuu cuA uAc uAA Guc uAc Guu ccc-3’
(13) c3WJ-Alexa647: 5’- GGA ucA Auc AuG GcA A(C6-NH)(Alexa647)-3’ (custom
ordered from Trilink)
(14) Survivin anti-sense:5’-UGA CAG AUA AGG AAC CUG C-3’
(15) Survivin anti-sense(scramble): 5’-CUC CCG GCC AUG GCC GCG GGA UU-3’
EVs purification:
EVs were purified using a modified differential ultra-centrifugation method(182).
Briefly, the fetal bovine serum (FBS) used for cell culture was spun at 100,000 × g for 70
min to remove the existing serum exosome. The supernatant of HEK293T cell culture
(EVs enriched medium) was harvested 48 h after cell plating, and was spun at 300×g for
10 min to remove dead cells, followed by spinning at 10,000 × g for 30 min at 4 °C
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degree to remove cell debris and/or microvesicles. EVs were concentrated from the
culture medium by using an Opti-prep Cushion procedure (183). The Opti-prep cushion
offers an iso-osmotic pressure and prevents physical disruption of the exosome. A 200 μL
of 60 % iodixanol (Sigma) was added to the bottom of each tube to form a cushion layer.
After spinning at 100,000 × g for 70 min at 4 ºC using Beckman SW28 rotor, the EVs
migrated and concentrated to the interface layer between the 60 % iodixanol and the EVs
enriched medium. 1mL of the fraction close to the interface and cushion was collected. A
6 mL EV solution was further washed with a 30mL PBS in a SW28 tube that contained
50 µL of 60 % iodixanol cushion, and spin at 100,000 × g for 70 min at 4 ºC. The pellets
in the cushion were all together collected and were suspended in 1 mL of sterile PBS for
further use.
Cell culture, EM imaging, confocal microscopy, DLS measurement, and flow
cytometry:
Methods for cell culture, EM imaging, confocal microscopy, DLS and
flowcytometry have been reported (43,66,139). HEK293T, KB, LNCaP-FGC, PC-3 cells
were obtained from ATCC, LNCaP-LN3 were obtained from MD Anderson Cancer
Center. Cell cultures purchased from ATCC were authenticated by Short Tandem Repeat
(STR) prior to purchase and LNCaP-LN3 cells were authenticated prior to receiving the
cells as a gift. Each cell line was not tested for mycoplasma. While the KB cell line has
been listed as a misidentified cell line that has been derived by contamination of HeLa
cells, it serves as an ideal model in these studies. KB cells are known to overexpress
folate receptor that allows for proper specific targeting through the use of Folate on RNA
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nanoparticles. The derivation of the KB cell line will not affect using it as model to test
folate receptor targeting property of the RNA displaying EVs.
Nanoparticle Tracking Analysis:
Nanoparticle Tracking Analysis (NTA) was carried out using the Malvern
Nanosight NS300 system on EVs re-suspended in PBS at a concentration of 10µg of
proteins/ml for analysis. The system focuses a laser beam through the sample suspension.
These are visualized by light scattering, using a conventional optical microscope aligned
to the beam axis which collects light scattered from every particle in the field of view.
Three 10 sec video records all events for further analysis by NTA software. The
Brownian motion of each particle is tracked between frames, ultimately allowing
calculation of the size through application of the Stokes Einstein equation.
Size exclusion chromatography:
Sephadex G200 gel column was equilibrated with PBS and loaded with
fluorescently labeled EV samples. After washing with PBS, fractions were collected with
5 drops per well. The fluorescence intensity Cy5 or Alexa647 in the collected fractions
was measured using a microplate reader (Synergy 4, Bio Tek Instruments, Inc).
siRNA loading into EVs:
EVs (100 μg of total protein) and RNA (10 μg) were mixed in 100 μL of PBS
with 10 μL of ExoFect Exosome transfection (System Biosciences) followed by a heatshock protocol. Cholesterol modified RNA nanoparticles were incubated with siRNA
loaded EVs at 37 ºC for 45 min, then stay on ice for 1 h to prepare the RNA decorated
EVs. The decorative RNA nanoparticles were kept at ratio of 10 µg RNA nanoparticles
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per 100 µg of EV in protein amount. To purify RNA decorated EVs, 400 µL of RNA
decorated EVs was washed with a 5 mL PBS in a SW-55 tube that contained 20 µL of 60
% iodixanol cushion, and spin at 100,000 × g for 70 min at 4 ºC. The pellets in the
cushion were all together collected and were suspended in 400 µL of sterile PBS for
further use.
FBS digestion experiment:
15µl of the purified Alexa647-RNA decorated EVs were mixed with 30 µL of FBS
(Sigma), and incubate at 37 °C for 2 h. The samples were loaded into 1 % syner gel for
electrophoresis in TAE (40 mM Tris-acetate, 1 mM EDTA) buffer to test the degradation
of decorative RNAs. Gel was imaged with Typhoon (GE healthcare) at Alexa647 channel.
Assay the effects of PSMAapt/EV/siSurvivin on prostate cancer using qRT-PCR:
LNCaP-FGC cells were incubated with 100 nM of the PSMAapt/EV/siSurvivin
and controls including 3WJ/EV/siSurvivin and PSMAapt/EV/siScramble nanoparticles
respectively. After 48 h treatment, cells were collected and target gene down-regulation
effects were assessed by qRT-PCR. PC-3 cells were used as negative control cell line.
Cells were processed for total RNA using Trizol RNA extraction reagent
following manufacture’s instruction (Life Technologies). The first cDNA strand was
synthesized on total RNA (1 μg) from cells with the various RNAs treatment using
SuperScriptTM III First-Strand Synthesis System (Invitrogen). Real-time PCR was
performed using Taqman Assay. All reactions were carried out in a final volume of 20 μL
using Taqman Fast Universal PCR Master Mix and assayed in triplicate. Primers/probe
set for human BIRC5 and 18S were purchased from Life Technologies. PCR was
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performed on Step-One Plus real time PCR system (Applied Biosystem). The relative
survivin mRNA expression level was normalized with 18S RNA as internal control. The
data was analyzed by the comparative CT Method (ΔΔCT Method).
Due to the high reproducibility and consistency between cell cultures, in in vitro
studies it was predetermined that a sample size of at least n = 3 would allow for adequate
analysis to reach meaningful conclusions of the data. However, in in vivo studies, higher
variance are seen in tissue samples; therefore, a higher set of samples is required to
compensate for this natural variance. In these studies, n = 4 and the experiment repeated
in triplicates was completed. Samples and animals were randomized into groups
throughout the whole experiment.
Western blot and antibodies:
LNCaP-FGC cells were incubated with 100 nM of the PSMAapt/EV/siSurvivin
and controls including 3WJ/EV/siSurvivin and PSMAapt/EV/siScramble nanoparticles
respectively. After 48 h treatment, cells were collected and lysed with RIPA buffer
(Sigma) with a protease inhibitor cocktail (Roche). Primary antibodies used for western
blot analysis were rat anti-human surviving antibody (R&D system, AF886), rat antihuman β-actin (Abcam, ab198991), rat anti-human TSG101 (Thermo Scientific, PA531260).
Cytotoxicity assay:
The cytotoxicity of PSMAapt/EV/siSurvivin was evaluated with a MTT assay kit
(Promega) according to the manufacture’s protocol. LNCaP-FGC and PC-3 cells were
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treated with EVs in triplicate in 96-well plate. After 48hr cell survival rate was analyzed
by the MTT assay on microplate reader (Synergy 4, Bio Tek Instruments, Inc).
In vivo targeting assay of tumor xenograft after systemic injection of EVs:
To generate prostate cancer xenograft mice model, male athymic nude Nu/Nu (68 weeks old) mice (Taconic) were used. 2 ×106 LNCaP-LN3 cells in 100 μL of PBS
mixed with equal volume of Matrigel matrix (Corning life science) was injected to each
mouse subcutaneously. When the tumor reached a volume of ~500mm3, the mice were
anesthetized using isoflurane gas (2 % in oxygen at 0.6 L/min flow rate) and injected
intravenously through the tail vein with a single dose 2 mg/kg of EVs/mice weight.
Whole body imaging (Excitation 650 nm/ Emission 668 nm) was carried out at 1 h, 4 h,
and 8 h post EVs administration using IVIS Spectrum Station (Caliper Life Sciences).
The mice were euthanized after 8 h, and organs and tumors were taken out for
fluorescence imaging to compare the biodistribution profiles of EVs. This animal
experiment was done with a protocol approved by the Institutional Animal Care and Use
Committee (IACUC) of The Ohio State Univeristy.
In vivo therapeutic effect of EVs in prostate cancer mouse models:
6-8 weeks old male nude mice (Nu/Nu) were purchased from Charles River
(Wilmington, MA). The mice were maintained in sterile conditions using IVC System
(Innovive). Tumor xenografts were established by subcutaneous injection of 2 × 106
cancer cells mixed with equal volume of Matrigel matrix (Corning life science) in the
flank area of the mice. PSMAapt/EV/siSurvivin, PSMAapt/EV/siScramble and PBS were
administered by tail vein injection, at dosage of 0.5 mg siRNA/5 mg EVs per Kg of mice
body weight, twice per week for three weeks. Two axes of the tumor (L, longest axis; W,
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shortest axis) were measured with a caliper. Tumor volume was calculated as: V =
(L×W2)/2. This animal experiment was done with a protocol approved by the Institutional
Animal Care and Use Committee (IACUC) of North Dakota State University. For tumor
inhibition assay, n = 10, the mice that did not develop tumor from the beginning were
excluded for analysis.
Statistics:
Each experiment was repeated at least 3 times with triplication for each sample
tested. The results were presented as mean ± standard deviation, unless otherwise
indicated. Statistical differences were evaluated using unpaired t test with GraphPad
software, and p < 0.05 was considered significant.
RESULTS AND DISCUSSION:
Design and construction of arrow shaped RNA nanostructures for display on EVs
surface.
The three-way junction (3WJ) (43,184) of the bacteriophage phi29 motor pRNA
folds by its intrinsic nature into a flat sheet with three angles of 60°, 120° and 180°
between helical regions (Figure 3.1a.) (184). The pRNA-3WJ was extended into an
arrow shaped structure by incorporating an RNA aptamer serving as a targeting ligand,
binding PSMA, a prostate cancer cell-surface receptor. The engineered pRNA-3WJ was
used to decorate EVs purified from HEK293T cell culture medium to create ligand
decorated EVs. HEK293T EVs were used as they are non-immunogenic and contain
minimal intrinsic biological cargoes (185). An Opti-Prep ultracentrifugation method was
used to purify EVs (see Methods(182)). Adding the iso-osmotic Opti-Prep cushion layer
for ultracentrifugation greatly enhanced reproducibility of exosome purification in yield
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(data not shown), as well as lessen physical disruption of exosomes by ultracentrifugation
pelleting. A single lipid molecule, cholesterol, was conjugated into the arrow tail of the
pRNA-3WJ to promote the anchoring of the 3WJ onto the EV membrane (Figure 3.1b.).
Cholesterol-tetraethylene glycol (TEG) spontaneously inserts into the membrane of EVs
that contain hydrophobic lipid core (186,187). The displaying of the RNA nanoparticles
to the surface of the purified EVs was achieved by a simple incubation of the cholesterolmodified RNA nanoparticle with the EVs at 37 °C for one hour. Electron Microscopy
(EM) imaging (Figure 3.1c.), Nanoparticle Tracking Analysis (NTA) and Dynamic Light
Scattering (DLS) revealed that the isolated native EVs were physically homogeneous,
with size centering at 110 nm(Figure 3.1d, Figure. 3.S1a-b), with a negative zeta
potential (Figure 3.1e). The purified EVs were further identified by the presence of
exosome marker TSG101 (188) by western blot (Figure 3.S1c). The yield of purifying
EVs from HEK293T cell culture medium was about 10-15 µg of EVs (measured as
protein concentration), or 0.1 - 1.9 × 109 EV particles (measured by NTA) per 106 cells.
EVs hold great promise as emerging therapeutic carriers given its intercellular
communication nature. They can enter cells through multiple routes including membrane
fusion, tetraspanin and integrin receptor mediated endocytosis, lipid raft mediated
endocytosis, or micropinocytosis; but there is no specificity regarding the recipient cells
(132,189). In order to confer specific targeting of the EVs to cancer cells, two classes of
targeting ligands including folate and PSMA RNA aptamer were conjugated to the 3WJ
for display on EVs. Folate is an attractive targeting ligand, since many cancers of
epithelial origin, such as head and neck cancers, overexpress folate receptors.(190)
PSMA is expressed at an abnormally high level in prostate cancer cells and its expression
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is also associated with more aggressive disease (191). A PSMA binding 2’-F modified
RNA aptamer (192) was displayed on EVs for enhancing targeting efficiency to prostate
cancer cells. For imaging, one of the pRNA-3WJ strands was end-labeled with the near
infrared fluorescent dye Alexa647 (Figure 3.1i). The size distribution and zeta potential of
RNA nanoparticle decorated EVs did not change significantly as measured by NTA and
DLS (Figure 3.1f-g, Figure 3.S1d).
Survivin, an inhibitor of cell apoptosis, is an attractive target for prostate cancer
therapy, since its knockdown can decrease tumorigenicity and inhibits metastases.(193)
In combination with the survivin siRNA loaded in the EVs(Figure 3.1i), the
PSMAapt/EV/siSurvivin were prepared for evaluating in vivo prostate cancer inhibition
efficacy (see section 5). To improve the enzymatically stability of siRNA, the passenger
strand was 2’-fluorine (2’-F) modified on pyrimidines, while keeping the guide strand
unmodified (50,51). For tracking the siRNA loading efficiency in EVs, the survivin
siRNA was fused to an Alexa647 labeled 3WJ core, and assembled into RNA
nanoparticles (Figure. 3.S1e). After loading siRNA into EVs, the size of EVs did not
change significantly as measured by NTA with a peak around 110 nm (Figure. 3.1f). The
loading efficiency for siRNA-3WJ RNA nanoparticles was around 80 % (Figure. 3.s1f),
controls without EVs or with only the ExoFect reagent showed as low as 15 % loading
efficiency using the same method.
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Figure 3.1.: RNA nanotechnology for decorating native EVs. (a) AFM image of
extended 3WJ of the motor pRNA of bacteriophage phi29. (b) Illustration of constructing
cholesterol labeled 3WJ on either the arrowhead arm or the arrow tail arm of the 3WJ.
(c). Electron microscopy image of EVs from HEK293T cells. (d). NTA profile and (e).
Zeta potential of EVs from HEK293T cells. (f).NTA profile and (g). Zeta potential of
PSMA aptamer displaying survivin siRNA loaded EVs. (h). 2D structure (left panel) and
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cells were loaded with therapeutic siRNA cargoes, and then displaying with RNA
nanoparticles harboring cholesterol for membrane anchorage and chemical ligand or
RNA aptamer for specific cell binding.

65

Figure 3.S1. Physopchemical characterization for EVs and RNA nanoparticles. a. A
representative NTA image of EVs purified from HEK293T cell medium. b. Particle size
distribution EVs from HEK293T cells measured by DLS. c. Western blot showed the
presence of TSG101 on EVs from HEK293T cells. d. Particle size distribution of
PSMAapt/EV/siSurvivin measured by DLS. e. Sequence and structure of pRNA-3WJ
fused with survivin siRNA. f. siRNA loading efficiency to EVs using ExoFect, the
controls without EVs or without ExoFect were tested.

66

3.2. Arrow head or arrow tail cholesterol labeling of the RNA nanoparticles resulted
in EV loading or membrane display, respectively.
a. Differentiation between entry or surface display on EVs using serum digestion.
The orientation and angle of the arrow shaped pRNA-3WJ nanostructure was
used to control the RNA loading or surface display to EVs. We performed serum
digestion experiment to confirm the localization of 2’F-RNA nanoparticles with EVs.
Although the 3WJ 2’F-RNA nanoparticles are relatively resistant to RNaseA, it can be
digested in 67 % fetal bovine serum (FBS) after incubation at 37 °C for 2 h (Figure.
3S2c). Alexa647-2’F-RNA nanoparticle-displaying EVs were purified from free RNA
nanoparticles by ultracentrifugation, then subjected to serum digestion experiment. It
turned out the Alex647-2’F-RNA with cholesterol on arrow tail decorated EVs were
degraded more than arrow head cholesterol decorated counterparts after 37 °C FBS
incubation (Figure 3.2a-d). The result can be explained by the protection of RNA
nanoparticles by EVs against serum digestion. Cholesterol to the arrow tail promoted
displaying onto exosomes surface thus being degraded; while cholesterol to the arrow
head promoted RNA nanoparticles entering EVs, thus the EVs provided protection
against serum digestion on the Alexa647-2’F- RNA nanoparticles.
The displaying of ligand on the outer surface of EVs might be caused by pRNA3WJ nanoparticles anchoring on the membrane without trafficking into the exosomes.
The arm which forms a 60° angle with its adjacent arm of the RNA nanoparticles can act
as a hook to lock the RNA nanoparticle in place, thereby preventing it from passing
through the membrane (Figure 3.2a). This locking on the membrane displayed the ligand
of either folate or PSMA RNA aptamer onto the EV surface.
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The concentration of FBS used in the serum digestion experiment was chosen
extremely high to purposely degrade the externally displayed RNA on EVs.

The

decorative PSMAapt-3WJ 2’F RNA nanoparticles have been shown to remain stable and
intact under physiological conditions.
b. Differentiation between entry into or surface display on EV by competition assay using
ligands to cancer cells.
As described above, when cholesterol was attached to arrow tail of pRNA-3WJ ,
the RNA nanoparticles were anchored on EVs membrane and the incorporated ligands
were displaced at the outer surface of the EVs (Figure 3.2a). An increase in uptake of
EVs to folate receptor overexpressing KB cell was detected through displaying folate on
EV surface by arrow tail cholesterol RNA nanoparticles (Figure 3.2 e, f). When
incubating with folate receptor low expressing MDA-MB-231 cells, arrow tail shaped
FA-3WJ/EV did not enhance its cellular uptake comparing to arrow tail 3WJ/EV (Figure
3.2g). The surface display of folate was further confirmed by free folate competition
binding assay, in which a base line of uptake by the FA-3WJ/EVs to KB cells was
established. A decrease in cellular uptake to KB cells was detected after adding 10uM of
free folate to compete with the cholesterol-arrow tail RNA nanoparticles decorated FA3WJ/ EV for folate receptor binding (Figure 3.2f). However, competition in uptaking of
arrow head FA-3WJ/EV (Figure 3.2h) to KB cells by free folate was much lower (24.8 ±
0.6 %) (Figure 3.2i), possibly due to partial internalization of the arrow head shaped
nanoparticle into the EVs, caused a lower displaying intensity of folate on the EVs
surface.
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EVs can mediate intercellular communications through transporting mRNA,
siRNA, microRNA or proteins between cells. They internalize into recipient cells through
multiple different pathways, including micropinocytosis, receptor-mediated endocytosis,
or lipid raft mediated endocytosis as reported (132). Although the natural process for EVs
uptake is not ligand dependent, the arrow tail cholesterol RNA 3WJ conferred successful
ligand dependent uptake by cancer cells, thus displaying cancer targeting property.
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Figure 3.2: Comparison of the role between arrow head and arrow tail 3WJ. (a-b)
Illustration showing the difference between arrow-head and arrow-tail display. (c) Syner
gel to test arrow head and arrow tail Alexa647-3WJ/EV degradation by RNase in FBS.
The gel was imaged at Alexa647 channel (d) and the bands were quantified by Image J. (ei) Assay to compare cell uptake of folate-3WJ arrow tail (e-g) and arrow head (h-i) on
folate receptor positive and negative cells.
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Figure 3.S2: RNA nanoparticles can be displayed on EVs outer surface by
cholesterol anchoring. a. 2’F RNA nanoparticles cannot be digested by RNaseA, but can
be digested in 67 % FBS after incubation for 2 h. To compare whether decorating EVs
with RNA nanoparticles can reduce its nonspecific cell entry, b. shows the schematic
drawing of EVs with or without RNA decoration, the EVs were labeled by loaded
Alexa647-3WJ nanoparticles. c. Flow cytometry tests the uptake of EVs by KB cells, 3WJ
2’F-RNA decorated EVs showed less cell entry comparing to undecorated EVs.
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3.3. Specific cancer targeting and gene silencing of the RNA-displaying EV
demonstrated in vitro.
Specific cancer cell targeting is one important prerequisite for applying nanovesicles to cancer therapy. To generate cancer cell targeting EVs, approaches to express
cancer cell specific ligand on EVs has been explored. One way to increase the specificity
of EV to target cell is to overexpress peptide ligands on the EV membrane proteins (139).
Neuron specific peptide RVG has been fused to EV membrane protein Lamp2b and
overexpressed on dendritic cells(139). GE11 peptide, which is a ligand to EGFR was
fused to the transmembrane domain of platelet-derived growth factor receptor (141).
RGD peptide was fused to EV protein Lamp2b, thus generated EVs can delivery
chemical drug doxorubicin specifically to tumor cells(194). One problem for using fusion
peptide for targeted exosomal delivery is that the displayed peptide can be degraded
during EV biogenesis. We explored here the method of displaying ligands onto EVs
surface post biogenesis to enhance its specificity. The specific targeting, delivery and
gene silence efficiency of the ligand displaying EVs were examined in cell culture. To
ensure RNase resistance, 2'-F modifications were made to the RNA nanoparticles placed
on the surface of EVs(43), while the thermodynamic stability of pRNA 3WJ provided a
rigid structure to ensure the correct folding of RNA aptamers.(43,44) PSMA aptamer
displaying EVs showed significantly enhanced binding and uptake to LNCaP cells
compared to EVs without PSMA aptamer, but not to the PC3 cells, which is a PSMA
receptor low expression cell line (Figure 3.3a). PSMA positive LNCaP prostate cancer
cells were used as a model to evaluate whether the siRNA were delivered to cancer cells
through

ligand

displaying

EVs.

Upon
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incubation

with

LNCaP

cells,

PSMAapt/EV/siSurvivin (PSMA aptamer/EV/Survivin siRNA) were able to knockdown
survivin expression at the mRNA level as demonstrated by real-time PCR (Figure 3.3b),
and protein level shown by western blot (Figure 3.S3). Cell viability and apoptosis was
detected by MTT assays (Figure 3.3c), indicating that LNCaP cells were undergoing
apoptosis as a result of survivin siRNA delivery.
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Figure 3.3: Specific binding and siRNA delivery to cells in vitro with PSMA aptamer
displaying EVs. (a) Flow cytometry (left) and confocal images (right) showing the entry
of PSMAapt/EV to PSMA(+) prostate cancer LNCaP cells. The confocal images are
overlap of Nucleus (Blue); Cytoskelton (Green); and EVs displaying with RNA (Red).
(b) PSMA aptamer mediated delivery of survivin siRNA by EV to PSMA(+) prostate
cancer cells assayed by RT-PCR. N = 3, experiment was run in three biological replicates
and three technical repeats, statistics were calculated using a two sided t-test with center
values presented as averages and errors as s.d. p = 0.016 for PSMAapt/EV/siSurvivin vs.
3WJ/EV/siSurvivin, p=0.013 for PSMAapt/EV/siSurivivn vs. PSMAapt/EV/siScramble. (c)
MTT assay showing reduced cellular proliferation. N = 3, experiment was run in three
biological replicates, and statistics were calculated using a two sided t-test with center
values presented as averages and errors as s.d. p = 6.8e-3. *p < 0.05, **p < 0.01.
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Figure 3.S3. Western blot detect the knockdown of survivin protein by EVs. Survivin
protein knocked down was detected in PSMAapt/EV/siSurvuvin PSMA positive LNCaP
cells, but not PSMA negative PC3 cells. The same construct loaded with scramble siRNA
or decorated without pRNA-3WJ were tested as negative controls.
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3.4. The ligand displaying EVs target tumors
The tumor targeting and biodistribution properties of ligand-displaying EVs were
evaluated. FA-3WJ/EVs were systemically administered via the tail vein into KB
subcutaneous xenograft mice model. Ex vivo images of mice healthy organ and tumors
taken after 8 hr showed that the FA-3WJ/EVs mainly accumulated in tumors, with low
accumulation in vital organs in comparison with PBS control mice (Figure 3.4a). The
results supports the assumption that displaying targeting RNAs on the EVs surface
reduces their accumulation in normal organs (141), and the ideal nano-scale size of RNA
displaying EVs facilitates tumor targeting via Enhance Permeability and Retention (EPR)
effects, thereby avoiding toxicity and side effects.
3.5. Complete inhibition of tumor growth by ligand-3WJ-displaying EV as
demonstrated in animal trials.
The therapeutic value of PSMA aptamer displaying EVs delivering survivin
siRNA for prostate cancer was further evaluated in vivo using LNCaP-LN3 tumor
xenografts generated in nude mice(195,196). Treatment with PSMAapt/EV/siSurvivin (1
does every 3 days, totally 6 doses were given) completely suppressed in vivo tumor
growth, compared to control groups (Figure 3.4b). EVs are biocompatible and well
tolerated in vivo as we did not observe any toxicity as indicated by body weights of the
mice, assessed 40 days after treatment (Figure 3.4c). The specific knockdown of survivin
was validated by real time PCR (24.3 ± 8.1 %, P < 0.05) (Figure 3.4d), Taken together,
the data showed that PSMAapt/EV/siSurvivin could deliver survivin siRNA specifically
into cancer cells upon systemic injection and achieve high therapeutic efficacy without
significant toxicity to the mice.
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The in vivo cancer growth inhibition effect was more significant than in vitro
MTT assays. The favorable effect and parameters of biodistribution, EPR effect of the
decoration by the negatively charged RNA motif explaining the difference in vitro and in
vivo, as found in the course of the study of RNA nanoparticles decorated EVs.
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Figure 3.4: Animal trials using ligands displaying EV for tumor inhibition. (a) Organ
images showing specific tumor targeting 8 hr after systemic injection of folate displaying
EVs to mice with subcutaneous KB cell xenografts. n = 2, two independent experiments.
(b) Intravenous treatment of nude mice bearing LNCaP-LN3 subcutaneous xenografts
with

PSMAapt/EV/siSurvivin

(0.6

mg/kg,

siRNA/mice

body

weight),

PSMAapt/EV/siScramble (0.6 mg/kg, siRNA/mice body weight), and PBS, injected twice
per week for three weeks. n = 10 biological replicates, 2 independent experiments, and
statistics were calculated using a two sided t-test with center values presented as averages
and errors as s.d. p = 0.347, 0.6e-2, 1.5e-6, 8.2e-8, 2.1e-7, 1.0e-7, 1.9e-7, 1.8e-6 for days
15, 18, 22, 25, 29, 32, 36, 39, respectively for PSMAapt/EV/siSurvivin compared to
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control. (c) Body weight of mice during the time course of exosome treatment. (d) RTPCR showing specific knockdown of survivin mRNA expression in prostate tumors after
EV treatment. n = 4 biological replicates, experiment was run three times, and statistics
were calculated using a two sided t-test with center values presented as averages and
errors as standard deviation.
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CONCLUSION
The use of RNA interference technology, such as siRNA, to knockdown gene
expression has been of great interest (197). The discovery of EVs, which are cell-derived
membranous vesicles that are universally released by many cell types (124) and play
important roles in intercellular signaling (136) advanced the field of siRNA delivery
study. EVs (124,136,198,199) are naturally capable of intracellular delivery of
biomolecules; and have nanoscale size and deformable shape with intrinsic ability to
cross biological barriers. EVs can directly fuse with the cell membrane through
tetraspanin domains or back-fuse with endosomal compartment membranes following
receptor-mediated endocytosis to release encapsulated cargo to cytosol. Therapeutic
payloads, such as siRNA can be fully functional after delivery to cells (124,136,198,199).
However, EVs lack selectivity and randomly fuse to healthy cells as well. To generate
specific cell targeting EVs, approaches to express cell specific peptide ligands on EVs
surface have been explored.(139,141) However, in vivo expression of protein ligands is
limited to the availability of ligands and depends on EV and ligand producing cell
types.(124,199) In addition, the use of protein ligands will result in larger sized particles
that can get trapped in liver, lung and other organs, and can stimulate the production of
host antibodies.(200) To date, there are no studies reporting the display of nucleic acid
based or chemical targeting ligands on EVs.
Herein, we applied RNA nanotechnology (26) to reprogram natural EVs for
specific delivery of siRNA to cancer models in vitro and in vivo (Figure 3.1a-c). Taking
advantage of the thermodynamically stable properties of pRNA-3WJ(43,44,72), we
generated multifunctional RNA nanoparticles harboring membrane anchoring lipid
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domain, imaging, and targeting modules. The natural arrow shape of the pRNA-3WJ
allowed for controlled entry or decoration on the surface of the EVs. With cholesterol
placed on the arrow tail of the 3WJ, the RNA-ligand was prevented from trafficking into
EVs, ensuring oriented surface display for cancer receptor binding. This was explicitly
shown in the cell decoration and folate competition assays (Figure 3.2b) and further
shown through the enhanced binding to LNCaP cells with the display of the PSMA
aptamer (Figure 3.3a). Additionally, the placement of cholesterol on the arrowhead
allowed for partial internalization of the RNA nanoparticle within the EVs (Figure 3.2a,
c). The addition of RNA nanoparticles to the surface of the EVs not only provided a
targeting ligand to the EV, they further added to the negative charge of the EV, thus
reducing the non-specific binding of RNA displaying EVs to untargeted tissues. The
cholesterol-TEG modified RNA nanoparticles should preferably anchor into the raft
forming domains of lipid bilayer of EVs (186), further studies will be necessary to
illustrate this process. Our in vitro decoration approach retained the favorable
endogenous composition of EVs as delivery vectors, thus eliminated the need of building
artificial endosome-escape strategies into the EV vectors comparing to using other
synthetic nanovectors for siRNA delivery.
Building on the confirmed RNA decorated EVs, we were able to specifically
target PSMA expressing prostate cancer cells and tumors in vitro and in vivo,
respectively. Furthermore, the EVs can deliver survivin siRNA to targeted prostate
cancer cells with a level that was able to completely inhibit the growth of LNCaP prostate
cancer xenograft. The PSMAapt nanoparticles provided a specific delivery of the EVs to
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the tumor while reducing accumulation in healthy organs which is normally seen in EV
delivery (141).
EVs are heterogeneous; their compositions differ depending on their parental cells
types. The interactions between EVs and immune system are also complex (201).
Leukocytes and dendritic cells derived exosomes are proposed to be potential candidates
for clinical therapeutics delivery vectors (202). But the exosome production scalability
and reproducibility still need further studies.
In summary, we demonstrated that we can effectively reprogram native EVs using
RNA nanotechnology. Nanoparticles orientation controls RNA loading or surface display
on EV for efficient cell targeting, siRNA delivery and cancer regression. The
reprogrammed EVs displayed robust physiochemical properties, adequate tumor site
localization, minimal healthy organ accumulation, high cancer cell specific uptake, and
efficient intracellular release of siRNA to suppress tumor growth in animal models with
unusually high efficiency.
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Chapter 4: RNA Nanoparticles Harboring Annexin A2 Aptamer Can
Target Ovarian Cancer for Tumor Specific Doxorubicin Delivery
This chapter (with some modification) is in submission at Molecular Therapy. Special
thanks to Dr. Thiviyanathan Varatharasa for help in preparation of 3WJc-endo28-3WJa
DNA strand for the experiments.
ABSTRACT:
Utilizing the state-of-art RNA nanotechnology platform, we report here the design
and construction of RNA nanoparticles harboring annexin A2 aptamer for ovarian cancer
cell targeting, and a GC rich sequence for doxorubicin loading that can deliver drugs to
ovarian cancer cells in a targeted manner. The system utilizes a highly stable three way
junction (3WJ) derived from packaging RNA of the phi29 bacteriophage as a core of the
nanoparticle. Annexin A2 aptamer was conjugated to one arm of the 3WJ. The highly
stable pRNA-3WJ structural motif provides a rigid core to the RNA architecture and
disfavors misfolding of aptamers when conjugated to other oligonucleotides, keeping
affinity and functions of all functionalities intact, and thus is of significance utility for
aptamer mediated targeted delivery. Nanoscale RNase-resistant RNA nanoparticles
remained intact after systemic injection in mice and strongly bound to tumors with little
or no accumulation in healthy organs 6 h post-injection, and the RNA
nanoparticle/doxorubicin conjugates showed enhanced toxicity to ovarian cancer cells,
but reduced toxicity to annexin A2 negative cells in cell toxicity assay. These results
suggest that the constructed nanoparticle doxorubicin can potentially enhance ovarian
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cancer targeted doxorubicin delivery for cancer treatment at lower doses with enhanced
efficiency.
INTRODUCTION:
Ovarian cancer is a highly metastatic and lethal disease with the highest mortality
rate of all cancers of the female reproductive system, although it is treatable when
detected early. Most patients have high-grade disease with metastasis at the time of
diagnosis due to vague clinical symptoms at early stages. The 5-year survival rate for
patients with advanced disease is very low despite cytoreductive surgery and
chemotherapy combination regimens. Furthermore, successful treatment is limited by the
high rate of chemo-resistance and emergence of undesirable toxicities. Therefore,
vehicles capable of targeted delivery of therapeutics to cancer cells with little collateral
damage to healthy cells and tissues are needed. Annexin A2 is a calcium-binding
cytoskeletal protein which is localized at the extracellular surface of endothelial cells and
multiple types of tumor cells (203). Annexin A2 plays an important role in the
angiogenesis and tumor progressing(204), targeting annexin A2 might be a strategy to
develop effective therapeutics for cancer treatment. Using Cell-SELEX (Systematic
Evolution of Ligands by Exponential Enrichment), a phosphorothiate modified DNA
(thio-DNA) aptamers Endo28 against annexin A2 expressed in the vasculature and
ovarian tumors obtained from human patients has been selected (205,206).
Doxorubicin is an anthracycline chemotherapy drug. It can slow or stop the
growth of multiple cancer cells and is an important component of ovarian cancer
treatment (207). Long circulating PEGylated liposomal doxorubicin is a FDA approved
drug for the treatment of recurrent ovarian cancer(208). Given that the promise of the
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delivery system could benefit the therapeutic effect of doxorubicin on ovarian cancers;
we explored the possibility of using RNA nanoparticles with targeting ligand for ovarian
cancer targeted drug delivery.
We recently discovered a phi29 pRNA three-way junction (3WJ) motif with
unusually robust thermostable properties that can be used as an RNA nanotechnology
platform to construct a new generation of therapeutic nanoparticles (43,53). The core
structure of pRNA-3WJ can be assembled from three pieces of short RNA
oligonucleotides, named 3WJa, 3WJb and 3WJc, with high efficiency forming a rigid
scaffold. The rigid pRNA-3WJ scaffold can ensure the correct folding of its connected
nucleic acid aptamers and other functionalities. We have demonstrated that RNA
nanoparticles built with the 3WJ scaffold while harboring different functional modules
retained their folding and independent functionalities for specific cell binding, cell entry,
gene silencing, catalytic function and cancer targeting, both in vitro and in animal trials.
The pRNA-3WJ nanoparticles are non-toxic and non-immunogenic (169). They are also
capable of penetrating across heterogeneous biological barriers to selectively target
cancer cells in mice and delivering therapeutics after systemic injection with little
accumulation in healthy organs and tissues.
The sequences for the thio-DNA aptamer will be incorporated into the pRNA3WJ 2’F-RNA scaffold to retain its authentic folding and functionality and in addition
will harbor the fluorescent imaging probe Alexa647. We hypothesize that this DNA/RNA
hybrid nanoparticle will retain the anenxin A2 targeting property in vitro and in vivo.
With addition of a fluorescent imaging probe Alexa647 and the chemotherapeutic drug
doxorubicin to the pRNA-3WJ scaffold, the nanoparticle can function as a drug carrier to
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enhance the accumulation of doxorubicin in ovarian cancer cells, thus reducing the
distribution of cargoes to other health organs. Load doxorubicin into the DNA/RNA
hybrid nanoparticles also changed the pathway of doxorubicin entering cells. Without
nanoparticles, doxorubicin enters cells mainly through passive diffusion; when
doxorubicin is intercalated into nanoparticles, it selectively enters annexin A2 positive
cells through receptor mediated endocytosis. Thus, the therapeutic effect can be enhanced
by changing the drug internalization pathway on cancer cells. An ovarian cancer
xenografts mouse model was utilized to evaluate the biodistribution of nanoparticles in
vivo.
MATERIALS AND METHODS
Construction of pRNA-3WJnanoparticles harboring Annexin A2 binding aptamer.
DNA/RNA hybrid nanoparticles were constructed using a bottom-up approach, as
previously described. Briefly, DNA oligo 3WJc-endo28-3WJa was synthesized by DNA
synthesizer, and Alexa647-3WJb 2’F-RNA, 3WJb-sph1 2’F RNA, Sph1-2’F-RNA were
prepared by RNA synthesizer using solid phase synthesis. The sequences are described
as below ( _* represents a phosphorothioated bond, lower case letter represents a 2’fluorine modified base ):
3WJc-endo28-3WJa DNA: 5’-GGA TCA ATC ATG GCA ACG CTC GGA TCG ATA
AGC TTC GCT CGT CCC CC*A GGC* AT*A G*AT* ACT CCG CCC CGT C*AC
GG*A TCC TCT* AG*A GC*A CTG TTG CCA TGT GTA TGT GGG-3’
Alexa647-3WJb 2’F-RNA: 5'-(Alexa 647) (C6-NH) ccc AcA uAc uuu Guu GAu cc-3'
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3WJb-Sph1 2’F-RNA: 5’- ccc AcA uAc uuu Guu GAu ccA Auc ccG cGG ccA uGG
cGG ccG GGA G-3’
Sph1-2’F- RNA: 5’-cuc ccG Gcc Gcc AuG Gcc GcG GGA uu-3’
3WJa 2’F- RNA: 5’-uuG ccA uGu GuA uGu GGG-3’
3WJc-2’F RNA: 5’-GGA ucA Auc AuG GcA A-3’
The RNA nanoparticle carrying a scramble aptamer sequnce was prepared by in
vitro transcription with Y639F T7 polymerase. The DNA template was prepared by two
step PCR using primer1 and 2 for first step, and primer 3 and 4 for second step PCR.
2’fluorine (2’-F) modified cytosine and uracil were used in the transcription reaction. The
transcribed RNA strand was purified by 8 M Urea, 8 % polyacrylamide gel ran in TBE
buffer (89 mmol/L tris-borate, 2 mmol/L EDTA). RNA bands of interest was excised
from the gel visualized by UV shadow on thin layer chromatography plates, and eluted
from gel with elution buffer (0.5 M Ammonium Acetate, 0.1 mol/L EDTA, 0.1 % SDS),
followed by ethanol precipitation.
Primer1: 5’-TAA TAC GAC TCA CTA TAC CGG ATC AAT CAT GGC AAG TTC
GGT TGT GTC GGC GAG TAT AG-3’
Primer 2: 5’- GGA TCA ACA AAG TAT GTG GGA TCG GCA TTA TAC GTA TAG
CA-3’
Primer3: 5’-GTA TAA TAC GAC TCA CTA TAG GGC CGG ATC AAT CAT GGC
AA-3
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Primer4: 5’-CTC CCG GCC ATG GCC GCG GGA TTG GAT CAA CAA AGT ATG
TGG-3’
Scramble template: 5’-GTC GGC GAG TAT AGG TGA AGT TGC CAT GTG TAT
GTG GGG TGA TGG ATT GCT ATA CGT AT-3’
Nanoparticles were assembled by mixing strands at equal molar concentrations in
PBS(w/Ca2+ Mg2+) buffer(0.1 g/L CaCl2, 0.2 g/L KCl, 0.2 g/L KH2PO4, 0.1 g/L MgCl26H2O, 8.0 g/L NaCl, 1.15 g/L Na2HPO4), the mixture was heated to 90 °C for 5 minutes
and snap cooled down on ice.
Load doxorubicin to Endo28-3WJ-Sph1 nanoparticles.
Doxorubicin (Sigma) solution (20 µM) was incubated with extended Endo283WJ-Sph1 or Scr-3WJ-Sph1 RNA nanoparticles (2 µM) in intercalation buffer (0.1 M
CH3COONa, 0.05 M NaCl, 0.01 M MgCl2) for 1h at room temperature. Then the free
doxorubicin was removed by passing through Sephadex G50 spin column (NucAwayTM,
Ambion). The loading efficiency of doxorubicin was monitored through measuring the
fluorescence intensity of doxorubicin with fluorometer (Horiba Jobin Rivin) at excitation
wavelength 480nm, emission 500-720 nm.
To measure the intercalation constant of Endo28-3WJ nanoparticle with
doxorubicin, increasing concentration of nanoparticles were incubated with 1.4µM of
doxorubicin, the fluorescence intensity of doxorubicin was measured. The fluorescence
quenching as a function of increasing aptamer concentration was plot and fitted into a
Hill equation with Origin to calculate the KD.
Release of doxorubicin from the nanoparticle –doxorubicin conjugates
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Drug release from the nanoparticle /doxorubicin conjugates was monitored using
dialysis bag with 3.5 kDa cutoff under sink condition(209). About 400 µL of Endo283WJ-Sph1/doxorubicin conjugate which contains 1 µM doxorubicin was dialyzed in
intercalation buffer at 37°C. 100 µL of releasing medium was collected at time point of 0,
0.7, 2.5, 4, 6, 8, 20, 24 h. Free doxorubicin was also dialyzed to test its release profile as a
control. The concentration of doxorubicin in release buffer was tested with fluorometer
(Horiba Jobin Rivin) at excitation wavelength 480nm, emission 500 to720 nm.
Serum stability assay
400 ng of Alexa647 labeled Endo28-3WJ nanoparticle were incubated in PBS
buffer containing fetal bovine serum (FBS) at final concentration of 10%. Samples were
taken at multiple time points, including 0, 0.5, 1, 2, 4, 8, 9, and 24 h after incubation at 37
°C. 8 % Native TBM polyacrylamide gel electrophoresis was applied to visualize RNA.
The gel was imaged at Alexa647 channel with Typhoon FLA 7000 (GE Healthcare;
Pittsburgh, Pennsylvania).
Nanoparticle size and zeta potential measurement by DLS
Apparent hydrodynamic sizes and zeta potential of assembled Endo28-3WJ
nanoparticles were measured by a Zetasizer Nano-ZS (Malvern Instruments; Malvern,
United Kingdom). RNA nanoparticles were measured at 1 μM in Diethylpyrocarbonate
(DEPC) treated water at 25 °C.
Cell culture
Human ovarian cancer cell line SKOV3 (American Type Culture Collection;
Manassas, Massachusetts) was cultured in McCoy’s 5A medium (Life technologies)
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containing 10% FBS, IGROV-1 cells were culture in RPMI 1640 medium (Invitrogen;
Grand Island, New York) containing 10 % FBS and 1 % gentamicin sulfate (Gibco),
HEK293T cells were cultured in DMEM medium (Life technologies) containing 10%
FBS, HMVECad cells were cultured in flask where its surface coated with attachment
factor (Gibco) with Medium 131(Gibco). All cells were cultured in a 37 °C incubator
with a 5 % CO2 and a humidified atmosphere.
Flow cytometry assay
Cells were trypsinized and rinsed with cell culture medium. Alexa647-labeled
Endo28-3WJ and the control 3WJ nanoparticles were each incubated with 2 × 105
SKOV3, IGROV-1 or HEK293T cells at 37 °C for 1 h, at the final RNA concentration of
100 nM.

After washing with PBS (137 mmol/L NaCl, 2.7 mmol/L KCl, 100

mmol/LNa2HPO4, 2 mmol/L KH2PO4, pH 7.4), the cells were re-suspended in PBS buffer
and subjected to flow cytometry assay. Flow cytometry assay was performed by the UK
Flow Cytometry & Cell Sorting Core Facility.
Confocal microscopy imaging
SKOV3, IGROV-1 and HEK293T cells were grown on glass cover slides in their
complete medium overnight. Alexa647-labeled Endo28-3WJ and the control 3WJ
nanoparticles were each incubated with the cells at 37 °C for 2 h at final concentration of
100 nM. After washing with PBS, the cells were fixed by 4% paraformaldehyde and
stained by Alexa Fluor® 488 phalloidin (Invitrogen; Grand Island, New York) for actin
and Prolong® Gold Antifade Reagent with DAPI (Life Technologies) for nucleus. For
visualize intracellular doxorubicin delivery, the nanoparticles were incubated with cells at
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final doxorubicin concentration of 1µM in PBS (with Mg2+, Ca2+) buffer for 6 h, then
stained with DAPI for image. Doxorubicin was visualized through a channel with
excitation at 480 nm, emission ranged from 530-650 nm. An Olympus FV1000 confocal
microscope (Olympus Corporation) was used for these assays.
Cytotoxicity assay
The cytotoxicity of RNA nanoparticles were evaluated with an MTT assay
(Promega, Madison, WI) following manufacture’s instruction. Briefly, SKOV-3 and
HEK293T cells were plated in a 96-well plate and cultured at 37 °C in humidified air
containing 5% CO2 overnight. The Endo28-3WJ-Sph1/Dox 2’F-RNA nanoparticle
conjugates and control nanoparticles, free doxorubicin were incubated with cells at 37 °C,
while keeping the final doxorubicin concentration to be 3 µM. After 48 h, 15 µL of dye
solution was added to each well and incubated at 37 °C for 4 h; 100 µL of solubilization
/stop solution was added to each well and incubated at room temperature for 2 h to
develop color. The absorbance at 570 nm was recorded using a microplate reader
(Synergy 4, Bio Tek Instruments, Inc, USA). The cell viability was calculated relative to
the absorbance of cells only control.
In vivo biodistribution and tumor targeting of RNA nanoparticles
SKOV-3 cells were cultured in vitro and subcutaneously injected under the skin
of 8-week-old female nude mice. A total of 2 × 106 cells were injected in solution.
Tumors were grown for 4 weeks until tumors reached a volume of 200 mm3. Mice were
then administered PBS, Endo28-3WJ, or 3WJ each with Alexa647 labels at a dose of 80
µg /mice through the tail vein. Mice were imaged for whole body fluorescence at time
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points of 0, 1, 2, 4, and 6 h with an In Vivo Imaging System (IVIS) imager (Caliper Life
Sciences; Waltham, Massachusetts). Upon the completion of the study, mice were
sacrificed, and tumors, hearts, kidneys, livers, and brains were collected and imaged by
the whole body imager for Alexa647 signal. Furthermore, tumors were fixed in 4%
paraformaldehyde with 10 % sucrose in PBS buffer at 4 °C overnight. Tumor samples
were then placed in Tissue-Tek Optimum Cutting Temperature compound (Sakura
Finetek USA; Torrance, California) for frozen sectioning (10 μm thick). Sectioned tissue
were then stained with DAPI and mounted with ProLong Gold Anti-fade Reagent (Life
Technologies; Carlsbad, California) overnight. Slides were then fluorescently imaged by
Olympus FV1000 Confocal Microscope System (Olympus; Pittsburgh, Pennsylvania).
RESULTS AND DISCUSSION
Construction of pRNA-3WJ nanoparticles harboring Annexin A2 binding aptamer
The phosphorothioate modified DNA (thio-DNA) aptamer targeting Annexin A2,
Endo28, was placed onto one end of the pRNA-3WJ 2’F-RNA, creating DNA/RNA
hybrid nanoparticles suitable for ovarian cancer targeted dug delivery. The DNA/RNA
hybrid nanoparticle with a two-piece design was found to have the highest assembly
efficiency, in which the sequence of thio-DNA aptamer Endo28 was connected to the
3’end of 3WJc and 5’end of 3WJa DNA, forming one DNA strand. The DNA oligo was
then assembled with 2’F modified Alexa647-3WJb 2’F-RNA to form a 2’F-RNA/thioDNA hybrid nanoparticle with 3WJ core structure, named Endo28-3WJ (Figure 4.1a).
The formation of hybrid nanoparticle was confirmed by native PAGE analysis (Figure
4.1b). The hybrid nucleic acid nanoparticles have a mean particle size around 8 nm
(Figure 4.1c), and negative charge with zeta potential around -20 mV (Figure 4.1d) as
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measured by Dynamic Light Scattering (DLS). They are stable in serum with a half-life
time of 4 h in 10 % FBS (Figure 4.1e).
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Figure 4.1. Characterization of endo28-3WJ DNA/RNA hybrid nanoparticles. (a).
Primary sequence and secondary structure of Endo28-3WJ nanoparticle predicted by M
Fold. (b). Native PAGE test the assembly of Endo28-3WJ nanoparticles. (c). Particle size
of Endo28-3WJ as determined by DLS. (d). Zeta potential of Endo28-3WJ nanoparticles
measured by DLS. (e). Serum stability assay showed the half-life of Endo28-3WJ in 10 %
FBS is around 4 h, which was calculated by quantify the bands at Ethidium bromide
channel. The gel image scanned at ethidium bromide channel is shown as insert.
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Loading Doxorubicin into Endo28-3WJ Nanoparticles and in vitro release
Doxorubicin can physically intercalate to nucleic acid nanoparticles by
preferentially binding to double stranded 5’-GC-3’ or 5’-CG-3’ sequences(210-212). To
increase loading ratio of doxorubicin per nanoparticle, we extended the arm of Endo283WJ at the 3’end of 3WJb with adding a 26 bp GC rich sequence named Sph1. The
extended Endo28-3WJ-Sph1 nanoparticle named Endo28-3WJ-Sph1 was assembled
through three single strands of nucleic acid (Figure.4.2a) with high efficiency as detected
by native PAGE (Figure.4.2b).
Doxorubicin (Dox), an anthracycline class drug, has fluorescence property that
can be quenched after being interacted with nucleic acid (213).The incorportation of
doxorubicin with extended nanoparticle, Endo28-3WJ-Sph1, was tested by fluorometer.
A decrease in fluorescence intensity was detected when incubate a fixed amount of
doxorubicin with an increasing concentration of Endo28-3WJ-Sph1 RNA nanoparticles
(Figure 4.2c). Evaluation of the predicted secondary structure of Endo28-3WJ-Sph1
nanoparticle reveals eleven possible sites for doxorubicin intercalation, as marked by red
asterisk in Figure 4.2a. The dissociation constant (KD = 140 nM) of the Endo28-3WJSph1/Dox physical conjugates was derived from the Hill plot in Figure 4.2c insert; while
the doxorubicin concentration was kept 1.4 µM. It suggests that Doxorubicin and RNA
nanoparticles spontaneously formed stable physical conjugates, and the molar binding
ratio of equilibrium doxorubicin per RNA nanoparticle is around 10 : 1. The number is
consistent with the predicted number of doxorubicin to be intercalated in each Endo283WJ-Sph1 RNA nanoparticles (Figure 4.2a).
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A study of Doxorubicin release from the nanoparticle–Doxorubicin physical
conjugates over time was conducted using dialysis tube with membrane cutoff of 3 kDa.
Upon dialysis, more than 80 % doxorubicin release was observed in 6 h with first order
kinetics (Figure 4.2d). A significant slower drug release rate at the initial stage suggests
this system is advantageous for in vivo systemically targeted delivery of doxorubicin.
Free doxorubicin showed a much faster release profile with more than 80 % release in
first hour (Figure 4.2d).
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Figure 4.2. Loading doxorubicin into Endo28-3WJ nanoparticles and its in vitro
release. (a). Secondary structure of Endo28-3WJ-Sph1 nanoparticles forming complex
with doxorubicin. Doxorubicin which is shown as red star intercalates into the
nanoparticles. (b). Native PAGE test the assembly of Endo28-3WJ-Sph1 nanoparticles,
the gel image at EtBr channel is shown as green, at Cy5 channel is shown as red. (c).
Fluorescence spectrum showing the intercalation of doxorubicin with Endo28-3WJ-Sph1
nanoparticles, the dissociation constant is calculated from the hill plot as insert. (d). In
vitro release profile of doxorubicin from the nanoparticle doxorubicin intercalates.
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Targeting of Endo28-3WJ nanoparticles to cancer cells in vitro
To test the targeting property of annexin A2 aptamer harboring pRNA-3WJ
nanoparticles in cell culture, the fluorescent Alexa647 labeled 3WJb 2’F-RNA strand was
assembled to Endo28-3WJ nanoparticles allow for tracking of the RNA nanoparticles.
The Endo28-3WJ nanoparticles were incubated with several cell lines, which have
different level of annexin A2 expression. IGROV-1(214), SKOV-3(215), human
microvascular endothelial cells (HMVECad) are tested as annexin A2 positive cells lines,
while HEK293T cells are annexin A2 negative and used as a negative control. Following
the RNA incubation and washing steps cells were analyzed by flow cytometry to confirm
the binding of the Endo28-3WJ nanoparticles. Flow cytometry analysis data showed that
Endo28-3WJ has stronger binding to IGROV-1 (71.2 %) than SKOV-3 (51.7 %), while
HEK293T showed a very low binding (17.3 %) similar to the non-binding 3WJ RNA
controls (Figure 4.3a). The result agrees with the annexin A2 expression level in cells as
reported (215). The flow cytometry data indicated that after fusing Endo28 aptamer to the
3WJ core structure, the annexin A2 aptamer retained its binding property to annexin A2
on cells after being incorporated into the pRNA-3WJ, which provides a scaffold for
building multifunctional nanoparticles, such as include additional sequences for loading
drugs.
RNA nanoparticles suitable for targeted therapeutics delivery need to be
internalized into their target cells for proper release of therapeutic agents. The entry of
the Endo28-3WJ nanoparticles into annexin A2 positive cells including IGROV-1 and
SKOV-3 was examined by confocal microscopy, and the annexin A2 low expression
HEK293T cells were used as negative controls. After incubating Alexa647 labeled
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Endo28-3WJ nanoparticles with cells, Endo28-3WJ showed clear internalization to
IGROV-1 and SKOV-3 cells; but very little signal was seen on HEK293T cells (Figure
4.3b). Additionally, low Alexa647 signal was seen around cells for the 3WJ nanoparticles
without annexin A2 aptamers (Figure 4.3b). These results suggest that Endo28-3WJ
nanoparticles enter the cells in an annexin A2 dependent fashion.
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Figure 4.3 The binding and internalization of Endo28-3WJ to annexin A2 positive
cells. (a) Flow cytometry test the binding of Alexa647 labeled Endo28-3WJ nanoparticles
with annexin A2 positive cells (IGROV-1 and SKOV-3), and annexin A2 negative cells
(HEK293T). (b) Confocal microscopy test the internalization of Alexa647 labeled
Endo28-3WJ to annexin A2 positive cells (IGROV-1 and SKOV-3) and annexin A2
negative cells (HEK293T).
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Intracellular delivery of doxorubicin to ovarian cancer cells in vitro
To determine if the extended DNA/RNA hybrid nanoparticles Endo28-3WJ-sph1
could deliver doxorubicin to annexin A2 overexpression ovarian cancer cell, confocal
microscopy imaging was performed. Both SKOV3 (annexin A2 positive) and HEK293T
(annexin A2 negative) cells were incubated with free doxorubicin, Endo28-3WJSph1/Dox or Scr-3WJ-Sph1/Dox RNA nanoparticle conjugates for 8hrs and then
analyzed by confocal microscopy. Scr-3WJ-sph1RNA nanoparticle with the similar
doxorubicin loading efficiency and also with a pRNA-3WJ core structure was used as
negative control. The SKOV-3 cells treated with Endo28-3WJ-Sph1/Dox exhibited
strong doxorubicin fluorescence signal similar to free doxorubicin in the confocal
microscopy assay. However, when treated with the scramble-3WJ-sph1/Dox intercalates,
the cells showed much weaker cellular uptake of doxorubicin (Figure 4.4d). The
doxorubicin after being released from Endo28-3WJ-sph1/Dox complex was found mostly
located in cytoplasm; in contrast, free doxorubicin was located in cell nuclei after the
same treatment (Figure 4.4b). When incubated with annexin A2 negative HEK293T
cells(Figure

4.4c),

both

Endo28-3WJ-sph1/Dox

and

Scramble-3WJ-sph1/Dox

intercalates showed weak uptake (Figure 4.4g,h). These results suggest that Endo283WJ-sph1/Dox physical conjugates can specifically deliver doxorubicin into annexinA2
positive cell lines.
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Figure 4.4 In vitro delivery of doxorubicin by Endo28-3WJ-Sph1 nanoparticles to
cells. Both annexin A2 psotivie SKOV-3 (a-d) and annexin A2 negative HEK293T cells
(e-h) were tested.

Nanoparticles harboring doxorubicin conjugated with scramble

aptamer was tested as negative control (d, h). The cells were treated with nanoparticles
for 6hrs and imaged. The doxorubicin channel is shown as red, cell nuclei stained with
DAPI is shown as blue. Endo28-3WJ-Sph1 nanoparticles are shown as green.
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Effects of Endo28-3WJ-Sph1/Dox conjugate on cell cytotoxicity
Cell cytotoxicity was evaluated with an MTT assay, which monitors cell
metabolic activity. The cytotoxicity effect of Endo28-3WJ-Sph1/Dox conjugates was
tested with both annexin A2 positive SKOV3 cells and annexin A2 negative HEK293T
cells. An equal concentration (3 µM) of doxorubicin from Endo28-3WJ-Sph1/Dox, and
controls including Scr-3WJ-Sph1/Dox and free doxorubicin were incubated with cells.
Endo28-3WJ-Sph1/Dox showed significantly higher toxicity on SKOV-3 cells than the
controls including free doxorubicin and Scr-3WJ-Sph1/Dox conjugates (Figure 4.5a).
Such a difference in cytotoxicity was not detected with HEK293T cells (Figure 4.5b).
The results suggest that the Endo28-3WJ-Sph1 nanoparticles are able to deliver
doxorubicin selectively to annexin A2 positive cells, and exert its cytotoxicity effect on
the targeted cells.
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Figure 4.5. Cell cytotoxicity assay for Endo28-3WJ-Sph1/Dox intercalates in vitro.
(a). Endo28-3WJ-Sph1/Dox showed significantly higher toxicity than the control groups
including free doxorubicin and Scr-3WJ-Sph1/Dox on anenxin A2 positive SKOV3 cells.
n=3 biological replicates, statistics were calculated using a two sided t-test with center
values presented as averages and errors as s.d. p = 1e-4 and 1.5e-3comparing Endo283WJ-Sph1/Dox to free doxorubicin and Scr-3WJ-Sph1/Dox respectively. (b) Endo283WJ-Sph1/Dox did not show significant difference on toxicity with the control groups
including free doxorubicin and Scr-3WJ-Sph1/Dox on anenxin A2 negative HEK293T
cells. n = 3 biological replicates, statistics were calculated using a two sided t-test with
center values presented as averages and errors as s.d. p = 7.8e-2 and 2.6e-1comparing
Endo28-3WJ-Sph1/Dox to free doxorubicin and Scr-3WJ-Sph1/Dox respectively.
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Targeting of Endo28-3WJ nanoparticles to cancer cells in vivo
Ovarian cancer xenograft mice model were developed through subcutaneous
injection of SKOV-3 cells to female nude mice. Tumors were fully developed after 4
weeks. 100 μL of 10 μmol/L solution of Alexa647 labeled Endo28-3WJ nanoparticles
were administered to the mice through tail-vein injection. Mice were whole body imaged
to monitor the biodistribution of nanoparticles in vivo at designed time points. The mice
were sacrificed after 6 hours and nanoparticle accumulation in the organs was tested by
imaging. Alexa647 was detected throughout the whole body of the mice after 30 min of
injection indicating nanoparticles successfully circulated through the mice. At early time
points, Alexa647 signal was detected in the tumor, liver, and bladder of the mice. After 6
hours, fluorescence signal was remained in xenograft tumor, while undetectable in all
healthy organs (Figure 4.6a). Confocal microscopy imaging of the tumor sections shows
specific targeting and accumulation of the Endo28-3WJ nanoparticles to the SKOV3
xenograft tumor, while the control group including 3WJ nanoparticles and PBS showed
much lower fluorescent intensity in tumor cells (Figure4.6b). The results demonstrated
that the 3WJ RNA nanoparticles harboring Annexin A2 aptamer are suitable for targeted
in vivo drug delivery to cancer cell.
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Figure 4.6. In vivo targeting of Endo28-3WJ to ovarian cancer xenograft in mice
model. (a). Organ image of mice to test the accumulation of Alexa647 labeled
nanoparticles in vivo 6 hr post systemic injection. (b) Confocal microscopy to test the
cellular distribution of Alexa647-Endo28-3WJ inside the tumor tissue.
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CONCLUSION:
Annexin A2, a calcium phospholipid binding protein, has been characterized in
many cancer cell activity including cell invasion and metastasis. It is well known that
annexin A2 is overexpressed in ovarian cancer cells (203). A DNA aptamer using
phosphorothioate-modified DNA nucleotides was generated through SELEX for specific
targeting of annexin A2 by Mangana et al. (206). The selected thio-DNA aptamer was
placed onto the ultrastable pRNA-3WJ motif, creating a DNA/RNA hybrid nanoparticle
that can specifically target and enter ovarian cancer cells. The polyvalence of the pRNA3WJ scaffold also allowed for harboring of imaging probes for tracking and therapeutics
for treatment. By incorporating a GC rich sequence specifically designed for the binding
of a chemotherapy drug, doxorubicin, efficient loading of the drug was achieved at
around 10 molecules per nanoparticle.
The nanoparticles showed a sustained release profile of doxorubicin, with the
drug release reaching 80 % in 6 hours, as compared to naked doxorubicin that reached
more than 80 % releasing within only 1 hour. Such sustained release will ensure that
majority of the loaded drug will be released after the carrier nanoparticle reaches the
targeted tumor site, thus reducing the distribution of toxic chemical drugs to the healthy
organs and minimizing the side effect.
Upon confirmation of annexin A2 targeting nanoparticles entering into ovarian
cancer cells, and proper loading/releasing profiling of doxorubicin, experiments were
expanded to test the delivery of doxorubicin to cancer cells in vitro. SKOV-3 cells are
known to overexpress annexin A2, and it is also resistant to multiple drugs including
doxorubicin. The Endo28-3WJ-Sph1/Dox complex showed significantly higher toxicity
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towards SKOV-3 cells than the scramble control and the free doxorubicin. This is
possibly caused by changing the drug intracellular trafficking pathway, as confocal image
showed that doxorubicin released from Endo28-3WJ-sph1/Dox nanoparticles mainly
accumulated in cell cytoplasm, different from the free doxorubicin which was located in
cell nuclei.
The in vivo biodistribution study showed a promising profiling with accumulation
of nanoparticles in tumors, but not healthy organs. Thus using the Endo28-3WJ
nanoparticle for cancer cell targeted drug delivery will benefit ovarian cancer patients
with reducing the side effect of cancer chemotherapeutics, and increasing its local
concentration in tumor microenvironment after systemic administration. Overall, the
results demonstrated that stable RNA nanoparticles can be constructed for the specific
targeting and treatment of ovarian cancers, expanding the application of RNA
nanoparticles for including chemotherapeutic delivery.
RNA nanoparticles were constructed using the pRNA-3WJ core from the phi29
packaging motor to harbor annexin A2 aptamer for delivery of doxorubicin to ovarian
cancer cells. The DNA/RNA hybrid nanoparticles were proven to remain chemically and
thermodynamically stable for in vivo application. The annexin A2-specific nanoparticles
produces good binding profiles with ovarian cancer cells at 50 nmol/L RNA and provided
specific delivery of doxorubicin to SKOV-3 ovarian cacner cells, with significant higher
toxicity than scramble nanoparticle controls.

The annexin A2 aptamer harboring

nanoparticles also showed specific targeting to ovarian cancer after systemic
administration in mouse xenograft, therefor demonstrated great potential as vehicle for
targeted drug delivery to treat ovarian cancer.
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Chapter 5: Discovery of a New Method for Potent Drugs Development
Using Power Function of Stoichiometry of Homomeric Biocomplexes or
Biological Nanomotors
This chapter was reproduced (with some modification) with permission from Pi F,
Vieweger M, Zhao Z, Wang S, and Guo P. “Discovery of a new method for potent drug
development using power function of stoichiometry of homomeric biocomplexes or
biological nanomotors.” Expert Opinion on Drug Delivery, 2016. 13 (1), 23-36. DOI:
10.1517/17425247.2015.1082544. Copyright 2016 Taylor and Francis. Special thanks to
Zhengyi Zhao for help in preparation of data for Figures 5.1 and 5.4.
ABSTRACT:
Multi-drug resistance and the appearance of incurable diseases inspire the quest
for potent therapeutics. We reviewed a new methodology in designing potent drugs by
targeting multi-subunit homomeric biological motors, machines, or complexes with Z > 1
and K = 1, where Z is the stoichiometry of the target, and K is the number of drugged
subunits required to block the function of the complex. The discussed rational behaves
similarly to Christmas decorations, where a number of light bulbs are connected in series
in an electrical circuit; failure of one bulb results in turn off of the entire lighting system.
In most multisubunit homomeric biological systems, a sequential coordination or
cooperative action mechanism is utilized, thus K equals 1. Drug inhibition depends on the
ratio of drugged to non-drugged complexes. When K = 1, and Z > 1, the inhibition effect
follows a power law with respect to Z, leading to enhanced drug potency. The hypothesis
that the potency of drug inhibition depends on the stoichiometry of the targeted biological
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complexes has been proved recently using a highly sensitive in vitro phi29 viral DNA
packaging system. Examples of targeting homomeric bio-complexes with high
stoichiometry for drug discovery are discussed. Biomotors with multiple subunits are
widespread in viruses, bacteria, and cells, making this approach generally applicable in
drug development.
INTRODUCTION :
The continuous escalation of drug resistance has been threatening human health
and life, i.e., many microorganisms including bacteria, viruses, and even cancer cells are
developing resistance to current chemotherapies. Drug resistance in cancer has partially
contributed to ~600,000 deaths in the USA in 2012(216). To combat the on-rising drug
resistance, different approaches for developing new drugs have been explored. One
method is to develop drugs that target novel mechanisms. Components highly important
for cancer cell growth have been explored as drug targets for the treatment of multidrug
resistant cancer(217,218). The first FDA-approved drug to treat multidrug-resistant
tuberculosis, bedaquiline, follows a novel mechanism of inhibiting the bacterial ATP
synthase of M. tuberculosis and other mycobacterial species(219). Another approach is to
use nano-drug carriers to enhance the binding efficiency of drugs to cancer cells(220223). A third approach is to develop new combinational drugs acting on multiple targets
to enhance its efficacy (224,225), including cocktail therapy(226). This involves
identifying multiple targets that when treated simultaneously lead to a synergetic
therapeutic effect and optimizing the design of multi-target ligands(227). Still, there is
unmet need for treating multi-drug resistant disease. Thus, new approaches for drug
development are needed to combat drug resistance.
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A new hypothesis that potent drugs can be developed by targeting proteins or
RNA complexes with high subunit stoichiometry was reported recently(228). The major
challenge for testing this hypothesis is to evaluate the significance of the target
stoichiometry and the binding affinity of the drug molecule with respect to its efficacy. In
order to quantitatively correlate the drug inhibitory efficacy to the stoichiometry of the
target biocomplexes, a well-studied multicomponent system is required, which allows an
empirical comparison of functional inhibition efficiency of individual components with
different numbers of subunits.
The DNA packaging motor of bacteriophage phi29 was an ideal model for testing
this theory. The morphology and stoichiometry of the individual components in the phi29
DNA packaging motor have been well studied. The Phi29 biomotor (Figure 5.1a) is
composed of three essential, co-axially stacked rings(34,229-231): a dodecameric
connector ring located at the vertex of the viral procapsid; a hexameric packaging RNA
(pRNA) ring bound to the N-terminus of the connector(34,232), and a hexameric ring of
ATPase gp16 attached to the helical region of pRNA(233-235). The stoichiometry of
pRNA was first determined using Yang Hui's Triangle (or binomial distribution) in
1997(236), and similar mathematical methods were applied to determine the
stoichiometries of the protein subunits (229). Furthermore, dsDNA packaging utilizes a
revolution mechanism without rotation to translocate its genomic DNA powered through
the hydrolysis of ATP(234,235,237-242). The copy number of ATP molecules required
to package one full Phi29 genomic dsDNA has been predicted to be 10,000(234,235,237241,243). Phi29 DNA packaging, thus, offers an ideal platform to test the novel concept
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described above: the dependence of the inhibitory drug efficiency on the stoichiometry of
its targeted biocomplex.
Although the theory of targeting multisubunit complexes for developing potent
drugs was reported and validated recently(228), real cases of targeting multisubunit
complex for new drug development have been practiced(244-246). Since multicomponent
biomotors are widely spread in nature(240,241,247,248), the approach of targeting
multisubunit complexes for potent drug development discussed here is generally
applicable, especially in developing new generations of drugs for combating the rising
acquired drug resistance in viruses, bacteria, and cancers (249-251).
5.1 Rationale for selection of multi-subunit biocomplexes as efficient drug targets
Inhibitory drugs are typically designed to bind selectively to a target site, thereby
blocking the site from interaction with other biomolecules leads to the loss of essential
activity of the biological target. This target can be a single element, composed of only
one subunit, or a complex consisted of multiple subunits, such as the biomotors of the
hexameric ASCE (Additional Strand Catalytic E) superfamily(234,252). Conventional
drugs are designed to inhibit pathogenesis through targeting of a single subunit molecule,
such as an enzyme or a structural protein of a virus. As discussed below, the key in
designing potent drugs lies in targeting multisubunit biological motors, machines, or
complexes as drug targets that follow a sequential coordination or cooperative
mechanism. The stoichiometry of the complex, Z, is larger than 1 and the number of
drugged subunits that are required to block the activity of the target complex, K, equals 1
(Z > 1 and K = 1). Similar to in-series connected decorative Christmas lights, where one
broken light bulb will turn off the entire chain, one drugged subunit will inhibit the entire
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complex and therefore biological activity. Sequential action or cooperativity in
multisubunit complexes has been widely reported in biological systems(253-257);
inhibiting any subunit leads to inhibition of the entire complex, or in other words K
equals 1.
For a conventional drug that inhibits its single subunit target (Z = 1) with
efficiency p, the fraction of undrugged target molecules q will be 1-p; and those
undrugged target molecules will remain active to maintain their biological function. In
this situation, the inhibition efficiency is proportional to the substrate targeting efficiency
p(253-255). When targeting a dimeric complex (Z = 2), for example, inactivating any
subunit results in inhibition of the whole complex. For a drug targeting a dimeric
complex with substrate targeting efficiency p = 0.9 (90 %), only 10 % of the first subunit
and 10 % of the second subunit remain active after drug targeting. Thus, the fraction of
undrugged complexes will be effectively reduced to 0.01, leaving 1 % of complexes
active. Since drug inhibition depends on the ratio of drugged to undrugged complexes,
the efficiency of the inhibition is proportional to the product of the inhibition of the
individual subunits, in other words, it follows a power law with respect to Z.
Consequently, a complex composed of Z subunits with the smallest number of
blocked subunits (K) to inhibit activity of the complex is 1, when p percent of subunits
are interacting with the drugs, the fraction of uninhibited biocomplexes will be qz and the
proportion of inhibition equals 1 − 𝑞 𝑍 .
5.1.1 Drug inhibition efficiency predicted by binomial distribution model
The scenario outlined above follows a binomial distribution which can hence be
used to outline the relation between drug inhibition efficiency and target stoichiometry in
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general. When the target element is a monomer, the inhibition efficiency can be
calculated using Equation 1, where p and q are the fractions of drugged (substrate
targeting efficiency) and undrugged (normal active elements) subunits, respectively (p +
q = 1).
X = (p + q) 1

(1)

However, when the target element contains multiple subunits, a higher order binomial
distribution (Equation 2) is required to calculate the ratio of active complexes, where Z
represents the total number of subunits (the stoichiometry) and M the number of drugged
subunits in one biocomplex.
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Z M
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The probability of drugged subunits (M) and undrugged subunits (N; M + N = Z) in any
given biocomplex can be determined by the expansion of Equation 2. When Z = 3, The
expanded form of Equation 2 ， ( p  q)3  p3  3 p 2q  2 pq2  q3  1 , displays the
probabilities of all possible combinations of drugged and undrugged subunits of a
homoternary complex composed of three (p3), two (p2q), one (pq2), or no (q3) drugged
subunits; the sum equals 1. Assuming that 70 % (p = 0.7) of subunits are inactivated by
bound drugs leaving 30 % (q = 0.3) unaffected, then the percentage of complexes
possessing at least two copies of normal subunits would be the sum of those possessing
one copy of drugged and two copies of undrugged wild-type subunits, 3pq2, and those
possessing three copies of native subunits is q3, i.e., 3pq2 + q3 = 3(0.7)(0.3)2 + (0.3)3 =
0.216. In another example, if a complex contains 6 subunits, and biological activity
requires 5 out of the 6 subunits to remain uninhibited, the fraction of active complexes in
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the total population equals the sum of probabilities of obtaining: 1) 5 and 2) 6 undrugged
subunits.
Using the binomial distribution, the probabilities that a population contains any
combination of undrugged versus drugged subunits can be predicted. The effect of the
targeting efficiency p on the probability of obtaining a given complex with M drugged
and N undrugged subunits is displayed in Table 1. The probabilities are calculated using
equation 2, Z! p M q N , with the coefficients Z! obtained from Yang Hui’s Triangle,
M ! N!

M ! N!

which is also called Pascal's Triangle, or binomial distribution (Figure 5.1b)(258). The
use of Yang Hui’s Triangle and binomial distribution to determine the stoichiometry of
biological motor was published in Guo Lab in 1997(236,259) for RNA component and
restated in 2014 for protein component(229) in phi29 DNA packaging motor.
5.1.2 Cooperativity in multisubunit biocomplexes leads to high inhibition efficiency
The cooperativity of multisubunit biocomplexes is the key to high drug inhibition
efficiency. Cooperativity means that multiple subunits work sequentially or processively
to accomplish one essential biological reaction (237,254-256,260-264). Blocking any
subunit of the complex inhibits the activity of the whole complex. Many reactions
involving multiple subunits work cooperatively, e.g. assembly pathways in viral
assembly systems (253,265). An analogy to such a biological reaction mechanism is
given by the difference between parallel and series circuits. When a chain of light bulbs is
arranged in a parallel circuit, burning out one light bulb will not affect others, while in a
series circuit, breaking any one light bulb turns off the entire lighting system. The K
value, the smallest number of subunits that needs to be inhibited in order to inhibit
function of the light chain is therefore, K = 1. Thus, the K value is a key factor in
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estimating the probability of obtaining inactive nanomachines or biocomplexes by
combination and permutation of all subunits.
K = 1 is critical for obtaining ultrahigh inhibition. The foundation of the approach
in this report is the difference in inhibition probability for biocomplexes with the same
ratio of drugged target subunits but different K values. Biological systems display
complicated reactions that involve several steps and multiple components interacting in
series or parallel. Based on the binomial math model and cooperative nature of biological
reactions, we suggest that targeting of multi-subunit biocomplexes can serve as a tool to
develop highly potent drugs. In a conventional six-component system, when one drug is
designed to target only the component #3 to stop the entire system, such a condition
resembles the model in equation 2 with Z = 1 and K = 1. Thus, the inhibition efficiency is
linear to the substrate targeting efficiency (p) of the drug. However, in a homohexameric
component system, the entire complex is blocked when a drug targets any subunit of the
hexamer, which resembles Z = 6 and K = 1. Thus, the probability of active target
complexes equals q6 (q = 1 - p). In other words, the drug inhibition efficiency is equal to
1-q6, which scales with the 6th power of q compared to linearly with q as for conventional
mono-subunit approaches (see Table 2).
Targeting a biological complex that exhibits a higher stoichiometry substantially
reduces the fraction of non-inhibited complexes. K=1 implies that drug binding to one
subunit inactivates the subunit, in which one drugged subunit is sufficient to inhibit the
function of the entire complex. As an example, a probability calculation for Z = 6 and K =
1 is given below. As all 6 (Z = 6) copies of the subunits are required for function, while
one drugged subunit (K = 1) is sufficient to block the activity, all elements possessing 1
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through 5 copies of drugged subunits are non-functional (Figure 5.1c). Only those
complexes possessing 6 copies of undrugged subunits are functional. The probability that
a complex contains 6 copies of unaffected subunits is q6 and therefore the inhibition
efficiency is 1-q6 (227,237,253,260,265,266).
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Figure 5.1. The morphology and stoichiometry of Phi29 DNA packaging motor. (a)
Illustration of Phi29 DNA packaging motor composed of 1 copy of genomic DNA
through a channel composed of three coaxil rings, a 12 subunit connector, 6 subunit
pRNA, 6 subunit ATPase gp16. (b) Bionomial distribution equation with its coefficient
displayed by Yang Hui Triangle. (c) Illustration of Z = 6 and K = 1, drug targeting any
subunit of a hexameric complex would block its function. Adapted from ref.(228) with
permission.
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Table 2. Probability of obtaining complexes containing M copies of drugged and N
copies of undrugged subunits
Z=1
Inhibited
Subunits (p)

Z=6

M=0,
N=1

M=1,
N=0

M=0,
N=6

M=1,
N=5

M=2,
N=4

M=3,
N=3

M=4,
N=2

M=5,
N=1

M=6,
N=0

0%

100%

0%

100%

0%

0%

0%

0%

0%

0%

10%

90%

9%

53%

35%

10%

1%

0%

0%

0%

20%

80%

16%

26%

39%

25%

8%

2%

0%

0%

30%

70%

21%

12%

30%

32%

19%

6%

1%

0%

40%

60%

24%

5%

19%

31%

28%

14%

4%

0%

50%

50%

25%

2%

9%

23%

31%

23%

9%

2%

60%

40%

24%

0%

4%

14%

28%

31%

19%

5%

70%

30%

21%

0%

1%

6%

19%

32%

30%

12%

80%

20%

16%

0%

0%

2%

8%

25%

39%

26%

90%

10%

9%

0%

0%

0%

1%

10%

35%

53%

100%

0%

0%

0%

0%

0%

0%

0%

0%

100%
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Consequently, for a drug with binding efficiency p, a larger stoichiometry of the
target complex substantially increases the inhibition efficiency. To illustrate, we compare
the fraction of non-inhibited complexes for Z = 6 and Z = 1, while keeping q = 0.4 and
K=1 fixed for both target systems. The fraction of non-inhibited complexes for Z = 1
amounts to qZ = 0.41 = 0.4, resulting in 1-0.4 = 60 % of inhibited complexes. In contrast,
for Z=6, the fraction of non-inhibited complexes is qZ = 0.46 = 0.0041 and therefore 10.0041 = 99.59 % of complexes are inhibited. The ratio of the remaining non-inhibited
complexes (0.4/0.0041 = 98) shows a 98-fold decrease in non-inhibited complexes for Z
= 6 compared to Z=1. At a targeting efficiency of p=0.9, the inhibition efficiency for Z =
6 is 1-qZ = 1-0.16 = 0.999999 resulting in a 10,000-fold increased inhibition efficiency
compared to Z = 1 (0.1/0.16 = 105, see Table 1). The binomial distribution indicates that
the inhibitory effect follows a power law with respect to the stoichiometry of the target.
Thus, for K = 1, the fraction of uninhibited biocomplexes equals qz; the larger Z, the
smaller qz, (as 0 < q < 1). That is to say when developing drugs with the same binding
affinity to their targets, the higher the stoichiometry of its multimeric target, the fewer
uninhibited targets will remain and the more efficient the drug will be.
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5.1.3 IC50 decreases as the stoichiometry of target complexes increases
The half maximal inhibitory concentration (IC50) is one parameter used to
evaluate drug efficacy. It quantitatively indicates how much of a particular drug is
required to reduce the activity of a given biological process by half. It is universally used
as a measurement of drug potency in pharmacological research. The median lethal dose
LD50, also known as 50 % of lethal concentration, is an important parameter to evaluate
the safety profile, i.e., acute toxicity of a drug. Most importantly, a larger ratio of LD50 to
IC50, results in a safer drug. By increasing the inhibition efficiency through targeting
components with high stoichiometry, the effective drug dosage is greatly decreased, thus
decreasing the IC50. As a result, the ratio of LD50 to IC50 increases, resulting in an
enlarged therapeutic window of the drug.
If we denote PIC50 as the percentage of drugged subunits needed to reach 50%
1/ Z
inhibition, then 1  (1  p IC50 )  50% Solving this equation, p IC50  1  0.5
.

Z

Figure 5.2 shows the relationship between stoichiometry (Z) and drug targeting level p to
reach the inhibition effect (IC), where p is a combined result of drug binding efficacy and
drug concentration (dosage). When the stoichiometry Z of the multimeric drug target
increases, the dosage of drug to reach IC50, IC20, or IC80 decreases, presented by the
percentage of drugged subunits. This clearly shows that as Z increases, p IC50 decreases,
and hence the drug is more potent.
Focusing on the stoichiometry of the target complex for drug development differs
from conventional approaches. Conventional drug molecules are sought to have a high
binding affinity to the target, which means we expect more drug molecules to bind to one
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target molecule. Here stoichiometry refers to the copy number of subunits within a
biocomplex or nanomachine that serves as the drug target. This idea agrees with a newer
model for predicting clinical drug efficacy, the receptor occupancy. Receptor occupancy
acts as a predictor for human pharmacodynamics and antihistamine potency and takes
into account both the affinity of the drug for its receptor and its free plasma concentration
(267).
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Figure 5.2. The relationship between the stoichiometry of homomeric target
complex (Z) and target complex inhibition effect (IC). Adapted from ref.(228) with
permission .
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5.2 Inhibition efficiency as a power function of target stoichiometry proved by Phi29
viral assembly system
The hypothesis that drug inhibition efficiency follows a power function with
respect to the target stoichiometry has been proved using the Phi29 viral assembly system
(268). This well-defined in vitro assembly system is composed of four components, each
of which is comprised of different subunits that can act as the nano-machine target.
Inhibition of viral assembly is achieved using mutant components that represent drugged
target components. The inhibition efficiencies were analyzed with Yang Hui’s triangle
for targeting each of the Phi29 DNA packaging motor components. Binomial distribution
analysis of these viral assembly competition assays confirmed the concept that drug
targeting biological complexes with higher stoichiometry results in a higher efficiency
than drugs acting on a single subunit target.
The highly sensitive in vitro Phi29 assembly system was used to determine the
inhibition efficiency of drugs targeting multi-subunit complexes (236,253,259,269), thus
validating a new method for developing potent drugs. The bacteriophage Phi29 DNA
packaging motor contains one copy of genomic dsDNA, 6 copies of packaging RNA, 6
copies of ATPase protein gp16, and consumes more than 10,000 copies of ATP during
genome packaging. The hexameric stoichiometry of Phi29 pRNA has been extensively
shown using single-molecule techniques(268), AFM imaging(47,48), pRNA crystal
structure

determination(184),

and

statistical

evaluations(236).

The

hexameric

stoichiometry of Phi29 gp16 has been proved by native gel binding, capillary
electrophoresis assays, Hill constant determination, and by titration of mutant subunits
using binomial distribution(234,237). The copy number of ATP molecules was calculated
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based on the fact that 6 ATP molecules are required to package one pitch of dsDNA
containing 10.5 base pairs (270), thus one ATP is used to package 1.7 base pairs of
dsDNA. The entire Phi29 genome is composed of 19,400 base pairs, thus, it is expected
that more than 10,000 ATP molecules are required to package an entire Phi29 genome.
The availability of a motor system with multiple well-defined and characterized
components makes an ideal disease model for the analysis of drug inhibition efficiency
versus the subunit stoichiometry of individual subcomponents within the same assay.
Inhibition efficiencies were determined for ATP, pRNA, ATPase gp16, and DNA
as drug targets with stoichiometries of 10,000, 6, 6, and 1, respectively. Among these
components, targeting of ATP showed the strongest inhibition, while drugged mutant
pRNA and mutant gp16 still showed stronger inhibitory effects than mutant DNA
(Figure 5.3). For example, adding 20 % mutant DNA caused 20 % inhibition of viral
assembly, while 20 % of drugged mutant pRNA exerted 74 % of inhibition on viral
assembly and 20 % of γ-S-ATP almost completely inhibited the viral assembly,
indicating that higher stoichiometry results in stronger inhibition efficacy.
The target with ten-thousand-subunits showed higher inhibition than those with
six subunits, which in turn showed higher inhibition than the single subunit target. In
conclusion, these results show that inhibition efficiency displays a power function with
respect to the stoichiometry of the target biocomplexes. Drug inhibition potency depends
on the stoichiometry of the targeted components of the biocomplex or nano-machine.
Since bio-motors share certain common structural and operational mechanisms across
viruses, bacteria, and other cells, this approach has general application in drug
development.
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Figure 5.3. Comparing Phi29 viral assembly inhibition efficiency by targeting
components with different stoichiometry. Components in the system with different
stoichiometries were tested as drug targets (left pannel): DNA with stoichiometry of 1,
ATPase gp16 with stoichiometry of 6 (right upper pannel), pRNA with stoichiometry of 6
(right lower pannel), and ATP with stoichiometry of 10,000. Adapted from ref.(228) with
permission.
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5.3 Wide-spread distribution of biomotors with multiple subunits or high order
stoichiometry
Biological systems contain a wide variety of nanomachines with highly ordered
stoichiometry that are essential for DNA replication, DNA repair(271), homologous
recombination, cell mitosis, bacterial binary fission, Holliday junction resolution(272),
viral genome packaging(273), RNA transcription, nuclear pore transport, as well as
motion, trafficking, and exportation of cellular components. Here we use biological
motors as an example to elucidate the rationale of Z > 1 and K = 1. These biological
motors can generally be classified into three categories according to their DNA
transportation mechanism: linear motors, rotation motors and the newly discovered
revolution motors(237,241,248). High order stoichiometries are wildly observed among
biomotors, especially in rotation and revolution motors. Thus, biomotors are feasible
targets for the development of potent inhibitory drugs that exploit the power law behavior
of the subunit stoichiometry.
5.3.1 Rotation nanomachines
FoF1 ATP synthase and helicases are representatives of rotary motors (274,275).
FoF1 ATP synthase is a ubiquitous membrane enzyme that plays a key role in biological
energy metabolism (276,277). It consists of two linked rotary motors, F1 and Fo, which
are distinct in structure and function. F1 ATPase, forming the catalytic core, shows strong
ATP hydrolysis activity. It is composed of 5 subunits (33111), with three  and three
 subunits forming a hexameric ring with part of a long coiled coil  subunit. Fo is the
proton pore that is embedded in the membrane, it consists of at least 3 subunits (a1b1c8-15)
whereby subunit c differs among species.
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Helicase DnaB is a hexameric nanomachine (Figure 5.4a) that unwinds dsDNA
in front of the replication fork during DNA replication(278,279). Recently, a hand-overhand translocation mechanism was proposed for DnaB based on the crystal structure of
the DnaB hexamer complexed with ssDNA and GDP-AIF4 (280). In this mechanism, the
5’-3’ translocation of the subunits at a stepsize of two nucleotides is coupled with the
sequential hydrolysis of NTP (281). The sequential hand-by-hand migration of the
individual subunits results in DNA translocation.
RecA, a family of ATP-dependent recombinases, plays an important role in
dsDNA repair and genetic recombination in Archaea, Bacteria, and Eukaryota. It can
interact with ssDNA forming right-handed helical filaments as a complex with
approximately six monomers of RecA per turn (Figure 5.4b)(282,283). Electron
microscopy studies have demonstrated that ATP binding induces a re-orientation between
the RecA ATPase domains, resulting in the relative rotation of the protein on DNA
substrate during DNA translocation powered by ATP hydrolysis.
5.3.2 Revolution nanomachines
All the dsDNA viruses known to date utilize similar mechanisms to transport their
genome into preformed protein shells during replication. For example, Bacteriophage
phi29, HK97, SPP1, P22, and T7 all share a common revolution mechanism for dsDNA
packaging that employ a hexameric ATPase and predominantly dodecameric connector
channels for packaging dsDNA. The phi29 DNA packaging motor is composed of three
coaxial rings: a dodecameric channel ring and an ASCE hexameric ATPase linked by a
hexameric ring of pRNA (Figure 5.4c)(184,234,268). During genome packaging, more
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than 10,000 ATP molecules are consumed by the hexameric ATPase as energy source to
drive the translocation of one copy of the dsDNA genome(270).
The ASCE superfamily, including FtsK-HerA superfamilies and the AAA+
(ATPases associated with diverse cellular Activities), is a clade of nanomachines that
display a hexameric arrangement(284-287) of subunits. Their biological function is to
convert chemical energy from ATP into mechanical motion(234,243,288,289), typically
associated with conformational changes of the ATPase enzyme (234,290,291).
FtsK belongs to the ASCE superfamily. It is a multi-domain protein composed of
a C-terminal ATPase domain FtsK(C) containing α, β and γ sub-domains, an N-terminal
membrane-spanning domain FtsK(N) and a 600-amino acid linker(292-294). It is
responsible for conjugation between bacterial cells and dsDNA bidirectional
translocation(295,296). It has been proposed that FtsK subunits acts in a sequential
manner employing a revolution mechanism to translocate dsDNA(297,298). The crystal
structure and electron microscopy of FtsK(C) demonstrates formation of a ring-like
hexamer with DNA passing through the hexameric ring (Figure 5.4d)(298,299).
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Figure 5.4. Widespread biomotors or nanomachines are composed of multisubunit
complex. (A) Rotation nanomachine DnaB helicase is a hexamer (280) (PDB ID: 4ESV),
(B) rotation nanomachine RecA motor protein is a hexamer (283) (PDB ID: 1N03), (C)
revolution Phi29 DNA packaging motor contains a hexameric pRNA (184), (D)
revolution DNA motor protein FtsK is a hexamer (298) (PDB ID: 2IUU).
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5.4 Targeting biocomplexes for developing potent drugs
As illustrated above, drug efficiency follows a power function of the
stoichiometry of the subunits of the multimeric target biocomplex. Targeting
biocomplexes with higher stoichiometry therefore can lead to the development of more
potent drugs. Experimentally, approaches targeting receptor dimers, hetero- and homooligomers for drug screening open exciting possibilities for drug discovery and
development(300).
5.4.1 Targeting homomeric channel proteins for drug development
In the history of drug development, one important property of most channel
protein receptors has been overlooked, their stoichiometry. As a matter of fact, many
channel proteins are expressed as dimers or oligomers on cell membrane, including most
G-Protein-Coupled Receptors (GPCR) proteins (300). Targeting of GPCR hetero- and
homo- oligomers is generally starting to be considered for drug development. Therefore,
new models for multisubunit protein binding are being developed(300). Cooperative
binding affinity between ligand and multisubunit targets has been reported and
cooperativity factors were calculated by fitting to the Hill equation(237,300).
The ATP-sensitive homotrimeric P2X7 receptor (P2X7R) acts as a ligand-gated ion
channel. It forms a chalice-like channel with three ATP binding sites localized at the
interface of the three subunits. Occupancy of at least two of the three sites is necessary
for activation of the receptors which results in opening of the channel pore allowing
passage of small cations (Na+, Ca2+, and K+). P2X7R has received particular attention as
a potential drug target for its widespread involvement in inflammatory diseases and
pivotal roles in central nervous system (CNS) pathology (244). These concepts will
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broaden the therapeutic potential of drugs that target multi-subunit channel proteins,
including receptor heteromer-selective drugs with a lower incidence of side effects. They
will also help to identify novel pharmacological profiles using cell models that express
heteromeric receptors.
5.4.2

Targeting homomeric enzyme for antibiotics development
Targeting of key enzymes in essential biosynthesis pathways is an important

approach for antibiotics development. Many key proteins in the fatty acid synthesis
pathway and nucleotide synthesis pathway are found to be multivalent. The highly
ordered oligomeric enzymes in biosynthesis pathways could be promising targets for
developing more potent antibacterial drugs. Some examples of developing potent drugs
by targeting multisubunit biocompelxes are discussed below.
Fatty acid synthesis is an essential lipogenesis process in both Gram-positive and
Gram-negative bacteria. A key enzyme in the fatty acid biosynthesis pathway is fatty acid
biosynthesis 1 (FabI), which is a homotetramer complex acting as the major enoyl-ACP
reductase present in burkholderia pseudomallei (Bpm). A recent X-ray structure study
revealed the binding mode of the inhibitor PT155 with the homo-tetrameric BpmFabI
(245) (Figure 5.5a). The substrate BpmFabI is a homo-tetramer, one PT155 molecule
bound to each monomeric subunit has shown significant promise for antibacterial drug
development(245). Another example of targeting multisubunit biocomplex as drug target
is found in the guanine nucleotide biosynthesis pathway to control parasitic infection.
Inosine

5’-monophosphate

dehydrogenase

(IMPDH)

is

a

homo-tetramer

enzyme(246)(Figure 5.5b), which plays an important role by catalyzing the oxidation of
IMP to XMP in guanosine monophosphate(GMP) biosynthesis(246).Structural
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characterization of IMPDH with chemical inhibitor drugs indicates that binding to the
repeating units shows a more potent inhibition effect(301).
These examples of successfully targeted homotetramer enzymes for potent drug
development further proved the importance of the stoichiometry of target homo-meric
complexes. When applying this method to search enzymes as drug targets, it is critical to
test whether the stoichiometry of the complexes (Z) is > 1, and the number of subunits
needed to inhibit to block biological function (K) equals 1.
5.4.3

Targeting homomeric drug transporters for drug development

The mechanism of drug transporter, very similar to that of the revolution motor,
involves entropy induced transitions by ATP. High stoichiometry of the target complex
is a key consideration in drug efficiency. Targeting multidrug efflux transporters with
high stoichiometry has a better chance to develop drugs for treating multi-drug resistant
disease. The structure of bacterial multidrug efflux transporter AcrB is composed of three
alpha-helix subunits, that connect to form a funnel around a central cavity (Figure
5.5c)(302). The multidrug exporter MexB from Pseudomonas aeruginosa also forms a
homotrimer (Figure 5.5d)(303). Pyridopyrimidine derivatives have been reported to be
promising drugs to treat multidrug resistant pathogens by specific inhibition of the
homotrimeric AcrB and MexB transporters[117]. The structural architecture of ABC
transporters consists minimally of two TMDs and two NBDs. These four individual
polypeptide chains combine to form a full transporter such as in the E. coli
BtuCD(304). Although the stoichiometry of the heterodimer is not very high, the
stoichiometry of ATP per transporter is high. It is involved in the uptake of vitamin B12.
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The TMDs of ModBC-A and MalFGK2-E have six helices per subunit. These unique
structural features can be used in target considerations.
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Figure 5.5. Examples of homomeric multisubunit complex as drug target for
developing potent drugs. (A) Tetrameric bpFabI is a key enzyme in fatty acid synthesis
in bacterial, inhibitor PT155 forms a tetrameric complex with BpmFabI (245) (PDB ID:
4BKU). (B) Inosine monophosphate dehydrogenase (IMPDH) (246) (PDB ID: 1AK5) is
a key enzyme in guanine nucleotide biosynthesis pathway, inhibitors have been
developed targeting the tetrameric IMPDH. (C) Bacterial multidrug efflux transporter
AcrB forms a homotrimer(302)(PDB ID: 1IWG). (D) Multidrug exporter MexB from
Pseudomonas aeruginosa forms a homotrimer(303)(PDB ID: 2V50).
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CONCLUSION AND FUTURE PERSPECTIVE
Targeting functional biological units with higher stoichiometries allows for higher
inhibition efficiencies. The inhibition efficacy follows a power law with respect to the
subunit copy number when targeting multimeric biocomplex, compared to a linear effect
of the drug-target binding affinity when targeting a single-subunit substrate. This new
concept outlined herein suggests that potent drugs can be developed by targeting
biocomplexes with high stoichiometries with the potential of complete inhibition of the
targets activity. Possibly, this method can further be applied to guide development of
dominant negative proteins for potent gene therapy, which can be incorporated into a
multimeric protein nanomachine and results in a change of its activity (305). Since biomotors share certain common structural and operational mechanisms across viruses,
bacteria, and cells, this approach has general applicability in drug development.
Living systems contain many elegant arrays, motors and nanomachines that are
composed of multiple identical subunits. As reported here, these homomeric
biocomplexes can serve as potent drug targets. For example, most members of the ASCE
family are hexamers(234,306-310). As these machines are common among living
systems, specificity and toxicity need to be considered. In the development of antibacterial and anti-viral drugs, specificity and toxicity is not problematic since the target
biocomplexes differ from those found in human cells and thus all targets are intended to
be killed nonexclusively. In the development of anti-cancer drugs, mutations in multiplesubunit biocomplexes of cancer cell will present ideal targets for potent drug
development.
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Drug discovery is a multidisciplinary science including the fields of medicine,
biotechnology and pharmacology. Aiming to find a method for developing drugs with
ultra-high potency, much effort has been placed in the screening of new drug compounds,
uncovering of new drug targets, and illumination of functional pathways, but little
attention has been paid to the exploration of new methods for the design and development
of more efficient drugs. Here we propose that the inhibition efficiency of a given drug
depends on the stoichiometry of the biocomplex or bio-machine that serves as drug
target. Here the notion of “stoichiometry” differs from the conventional concept in drug
development. Conventionally, stoichiometry refers to the number of drug molecules
bound to each substrate or cell membrane. In the current study stoichiometry refers to the
number of identical subunits that the target biocomplex is composed of. Phi29 viral
components with a series of variable but known stoichiometries were evaluated as mock
drug targets to test the hypothesis. Both in vitro and in vivo virion assembly assays were
employed to compare inhibition efficiencies for targets with differing subunit
stoichiometries. Viral inhibition efficiency was analyzed with Yang Hui's (Pascal’s)
Triangle (also known as binomial distribution) (Figure 5.1), as shown in equation 2.
It was observed that inhibition efficiency of virus replication correlates with the
stoichiometry of the drug target. The inhibition efficacy follows a power law behavior
where the percentage of uninhibited biocomplexes equals 𝑞 𝑍 (see equation 2). For a
system with fixed q and K values, the inhibition efficiency thus depends on Z, the number
of subunits within the target biocomplex or bio-machine. This hypothesis is supported by
empirical data that a target with ten-thousand-subunits shows higher inhibition effect than
a target with six subunits, which in turn shows higher inhibition than a single-subunit
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target (Figure 5.3). The unconventional hypothesis described in this article for the
development of potent drugs with power function behavior with respect to the target
stoichiometry can be foreign or even outlandish to the main force of the pharmaceutical
field. The approach of developing highly potent drugs through targeting of protein, RNA
or other macromolecule complexes with high stoichiometry has never been reported due
to challenges to prove the concept.
Traditionally, it is almost impossible to prove this concept by comparing
efficacies of two drugs where one of them targets a biocomplex with multiple subunits.
When reporting the efficiency of this new approach, it is very difficult to distinguish
essentiality of the two targets in biological function; it is also very challenging to
compare the binding affinity of two different drugs to two different targets. For instance,
if two drugs target two stoichiometrically different complexes, it becomes extremely
difficult to prove whether the difference in drug efficiency is due to differences in their
target binding affinity or essential level of the target in the biological organism.
The mechanism of drug inhibition mainly relies on blocking an essential
biological target element from functioning. The target elements can be monomers or a
complex of multiple homosubunits; such as the biomotors of the hexameric ASCE
superfamily(234,252). Conventional drugs are designed to target a single subunit
molecule to inhibit pathogenesis, such as an enzyme or a structural protein of a virus. The
key in designing potent drugs is to target multi-subunit biological motors, machines, or
complexes with Z > 1 and K = 1, where Z is the stoichiometry of the complex and K is
the number of drugged subunit that are required in order to block the function of the

140

entire complex. Similarly, in a series circuit Christmas decorative light chain, one broken
light bulb will turn off the entire lighting system.
In most, if not all, multi-subunit biological systems, sequential coordination or
cooperative action mechanisms are utilized, thus, K equals 1. Drug inhibition depends on
the ratio of drugged to the non-drugged complex. For K = 1, and Z > 1, inhibition
efficacy follows a power function with respect to Z, leading to an increased potency of
the drug since inhibition of any subunit results in complete inhibition of activity. For a
drug designed to target a single-subunit molecule at targeting efficiency p, the fraction of
undrugged target molecules q that will remain active is 1- p. In this situation, the
inhibition efficiency is proportional to the substrate targeting efficiency p and the
inhibition efficacy is of the first order of p. Sequential action or cooperativity in multisubunit complexes has widely been reported in biological systems(253-255). Drugs
targeting a complex with multiple subunits can inhibit the complex activity if any
homosubunit of the target is inactivated. Thus, if the copy number of this cooperative
complex is Z > 1, and the least number of blocked subunit to inhibit complex activity (K)
is 1, the fraction of uninhibited biocomplexes is 𝑞 𝑍 , and the inhibition efficiency is 1 −
𝑞 𝑍 , where 1- q is the portion of drugged subunits.
The binomial distribution analysis allows prediction of the inhibition efficiencies.
For example, in targeting a six-subunit biocomplex with K = 1, the inhibition efficiency
is determined by drug binding to any one of the six homosubunits. Therefore, the
probability of inhibiting any subunit at random position is

1−𝑞6
1−𝑞

times higher than

inhibiting a monomer substrate. With this new elucidation and understanding of the
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concepts behind targeting of cooperative multi-homosubunit complexes, a new
generation of potent drugs may emerge in the near future.
Our discovery is an approach, not a drug. This approach will have general impact
in the development of drugs for many diseases such as cancer, viral or bacterial
infections. In living systems, biological machines or complexes with high stoichiometry
and operated by sequential cooperative action or coordination with Z > 1 and K = 1 are
ubiquitous. This class of biological machines is involved in many aspects of crucial
cellular processes to the survival of viruses, bacteria, and eukaryotic cells. For example,
multi-subunit biomotors are involved in chaperon, ATPase, ATP synthase, cell mitosis,
bacterial binary fission, DNA replication, DNA repair, homologous recombination,
Holliday junction resolution, nuclear pore transportation, RNA transcription, drug
transporters, muscle contraction, viral genome packaging, as well as motion, trafficking,
and exportation of cellular components. These systems use a sequential mechanism
similar to the serial circuit of the Christmas decoration lighting chain. Thus, our approach
will have broad application in drug development in many biological systems. Drugs
targeting to these motors will be highly efficient.
Biomotors belonging to the multi-subunit ATPase are widely spread in organisms,
including bacteria, viruses and cancer cells. Successful implementation of this new
methodology will lead to the development of the next generation of potent drugs. In fact
the first drug approved to treat multidrug-resistant tuberculosis, bedaquiline (219), is
acting on the ATP synthase which is a multisubunit biomotor (311-322). Treating
multidrug-resistant tuberculosis had been very challenging previously. Although this
drug’s inventors were not aware of the concept of targeting multisubunit complexes for
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potent drug development, the success in this drug conquering the tough Mycobacterium
tuberculosis organism supports the concept of using the multisubunit complex as a potent
drug target. Cancer or bacterial mutant multi-subunit ATPase can be used as target. The
drug developers can simply check the published literature and identify a multi-subunit
machine as the drug target. For cancer treatment, it is to find a multi-subunit machine
with mutation.
The concept of K = 1 for high efficiency inhibition may be impactful in gene or
protein therapy. By introducing the dominant negative protein(305) or inactive mutant
protein into the cell, either by intracellular expression or direct introduction of proteins,
which resembles the above illustrated approach and mechanism used for phi29 DNA
packaging motor systems (228,229,259,323)(Figure 5.3). This involves the incorporation
of mutant proteins, either intracellularly expressed or directly introduced, into a highly
multimeric complex that is identified as the target unit. For purposes of serving as a small
molecule drug target, a multimeric complex might be identified, such that binding of one
drug molecule to any one binding site on the complex will inactivate the whole complex.
The fact that the complex composed of Z subunits holding one drugged subunit will only
come into play as the drug concentration is at the high end. However, if the strategy was
to express a dominant negative protein, as has been done in recent cardiac gene therapy
with dominant negative phospholamban(305), a high inhibition efficacy will achieve. The
greater the value of Z the more the effect of the dominant negative protein subunit or
mutant subunit will be achieved.
Another possibility is the use of homomeric drug transporters (324,325) as drug
targets (see section 5.3). The mechanism of drug transporters is very similar to that of the
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revolution motor featuring an entropy transition induced by ATP. High stoichiometry of
target complex is a key consideration for achieving high drug efficiency. Targeting
multidrug efflux transporters with high stoichiometry has a better chance to develop
drugs for treating multi-drug resistant disease.
While the hypothesis behind this method might theoretically seem challenging,
elucidation of the mechanism should greatly facilitate application of this approach. Two
factors are essential for drugs development: efficiency and specificity. The strategy
described herein focuses on drug efficiency, while specificity is similar to the general
consideration in the development of chemicals and drugs. Nevertheless, design of potent
drugs to common machines or general targets is still possible. For example, if an
oncogenic mutant hexameric ATPase is found in one specific type of cancer cells, drugs
targeting to this mutation of the altered ATPase will not only be highly efficient but also
specific.
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Chapter 6: Future Direction and Current State of the Field
CONCLUSIONS AND FUTURE DIRECTION:
In this thesis work is described for the advancement of the RNA nanotechnology
towards therapeutically application. The main advantage of using RNA nanoparticles for
drug delivery remains in: 1. RNA nanoparticles functioned with nucleic acid based
aptamers can exert active targeting effect; 2. nucleic acid based therapeutics can be easily
conjugated to RNA nanoparticles and processed by dicer in vivo for siRNA and miRNA
release. Here in Chapter 2 of this dissertation, the development of bivalent 2’F-RNA
aptamer against cancer stem cell marker EpCAM was explored. By using previously
developed stable pRNA-3WJ motif as the core structure for constructing the divalent
RNA antibody library, and 2’-fluoro modifications on RNAs, a highly stable 2’F-RNA
aptamer against EpCAM was selected. The selected aptamer mimics antibody can
specifically deliver LNA based anti-miR21 to EpCAM positive cancer cells and knock
down miR21 levels in cancer cells. In Chapter 3 I explored utilizing the special
orientation of pRNA-3WJ to display RNA aptamers on the membrane surface of
extracellular vesicles. Taking the advantage that EVs are natural carrier for small RNAs,
and that RNA aptamers can recognize cancer cell marker and specifically target cancers,
the PSMA aptamer displaying EVs were tested as carrier for delivery therapeutic siRNA
to treat cancer. Results showed that the PSMA aptamer displaying EVs can deliver
survivin siRNA into prostate cancer cells in vitro and in vivo, and achieve very
significant effect in inhibiting xenograft prostate cancer growth in mice after multi-dose
treatment. In chapter 4 I explored the possibility of utilizing nanoparticle functionalized
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with aptamer against Annexin A2 to deliver doxorubicin to ovarian cancer cells. The
nanoparticles are optimized by elongating with GC rich dsRNA sequences to enhance the
doxorubicin loading efficiency. The nanoparticle doxorubicin intercalates have uniform
particle size around 8nm, and showed sustained release profile for doxorubicin in vitro.
They can deliver doxorubicin specifically to annexin A2 positive ovarian cancer cells
cytoplasm in vitro, and also showed targeting effect to subcutaneous xenograft ovarian
tumor in mice after systemic injection in vivo. All these results suggest the nanoparticles
harboring an aptamer are promising candidates for targeted delivery of chemical drugs to
treat cancer disease.
However, in order to fully prove the potential of the selected bivalent EpCAM
RNA aptamer for cancer treatment, future work is need. While it is proven that the
bivalent EpCAM aptamer A9-8 can bind to cancer cells and deliver anti-miR21 to cancer
cells in vitro, in vivo experiments should also be conducted to better evaluate the
functionality of this aptamer. Bio-distribution of fluorescent labeled EpCAM aptamer, as
well as the treatment effect of EpCAM aptamer harboring anti-miR21 on proper mice
model with subcutaneous tumor xenografts should be tested. For the newly developed
platform of utilizing orientation of pRNA-3WJ to control the display of RNA aptamers
on exosome surface, further experiments including exploring more advanced RNA
nanoparticle structures with lipid chemical modification to display ligands on exosomes
should be performed, the possibility of using aptamer displaying EVs for chemical drug,
miRNA, and mRNA delivery should also be explored. In order to fully prove the
potential of annexin A2 aptamer harboring nanoparticles for cancer specific doxorubicin

146

delivery, in vivo treatment experiment should also be conducted with proper mice model.
Further development of RNA nanoparticles into clinical trials should be considered.
CURRENT STATE OF THE FIELD:
Since the development of RNA nanotechnology in 1998 (34), the field has been
making great progress towards clinical application. The discovery of pRNA-3WJ
provided a platform to build thermodynamically stable multifunctional RNA
nanoparticles for therapeutics delivery. 2’F pyrimidine modification on RNA
nanoparticles make them resistant to nuclease. RNA nanoparticles functionalized with
aptamers or chemical ligand(49,66) can recognize their specific target; and the nanometer
scaled size of RNA nanoparticles further enhanced their tumor targeting efficiency
through EPR effect. Recently, RNA nanoparticles have been developed into vehicles for
delivering anti-microRNA(52,66), siRNAs(50,51) to cancer cells. Doxorubicin, the
anthracycline chemical drug can be easily loaded into the RNA nanoparticle through
intercalating into GC pairs. In the future, more sophisticated RNA nanoparticles will be
designed for controlled gene therapy and chemotherapy delivery. Multifunctional RNA
nanoparticles may also help to avoid the on rising multidrug resistance problem as they
can change the drug cell entry pathways (173).
The design of antibody shaped RNA library opened a new field for RNA antibody
development. Previously libraries for aptamer selection are designed to have a single
random region with 20 to 50 nucleotides; while this Y shaped RNA library containing
two random regions to enhance its binding affinity and specificity. The selected aptamers
can be directly fused with siRNA or miRNA sequences on the third arm for various in
vitro and in vivo applications. Except for drug delivery, RNA antibodies can be
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developed as new drugs for therapeutically application. The advantage of developing
RNA nanoparticle based therapeutics include: they can be developed in vitro, can be
designed to control its immunogenicity (54), can be batch produced as chemical drugs
and quality controlled.
Current popular EV engineering method is to co-express peptide or protein ligand
onto EV membranes during its biogenesis. This method faces the challenge of the
integrity of expressed ligand after EV secretion(326). Decorating EVs with cholesterol
modified RNA nanoparticles provides a new method to engineer EVs for targeted drug
delivery. This system takes the advantages of both extracellular vesicles for RNAi
delivery and also RNA nanoparticles for specific cancer cell targeting. More research on
this topic includes how to stabilize the association of RNA-cholesterol with EVs
membranes, how to use EVs for other gene therapeutics delivery such as miRNA, mRNA
and protein, as well as large scale production of high quality EVs.
After around two decades of growth, the field of RNA nanotechnology has
conquered lots of hurdles. With the continuous researching on this area, we wish this
field can grow forward towards industrial and clinical application.

Copyright © Fengmei Pi 2016
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